Although chronic bronchitis and pulmonary emphysema are distinct disorders, they often coexist in the patient and it can be difficult to determine the relative importance of each condition in the individual case. The term ‘COPD’ often applies to a combination of the two. In emphysema, the fine architecture of the alveoli is damaged, leading to impairment of ventilatory capacity. There is probably little that can be done to reverse this destruction (although some clinicians feel that bioavailable silica and herbs rich in this mineral, such as Equisetum and Urtica can help restore lung architecture).
In contrast, chronic bronchitis is a syndrome that can develop in response to long-term exposure to various types of irritants to the bronchial mucous membranes. These include cigarette smoke, dust and automobile or industrial air pollution, especially in conjunction with a damp climate. Acute infection is usually a precipitating or aggravating factor and chronic infection is usually present, with regular acute episodes. Hence, there are many factors in chronic bronchitis that are treatable, and long-term herbal treatment can dramatically alter the course of chronic bronchitis.
In chronic bronchitis, ventilatory capacity is reasonably preserved but hypoxia, pulmonary hypertension and right ventricular failure occur early – ‘the blue bloater’. In emphysema, the impairment of ventilatory capacity and exertional dyspnoea lead to the sufferer being labelled a ‘pink puffer’. A mixed syndrome is most common and all patients should be treated along the following lines, regardless of their clinical label. The treatment outcome will, however, depend on how much the changes in their lungs can be reversed.
In chronic bronchitis there is overactivity of the mucus-secreting glands and goblet cells. The vast excess of mucus coats the bronchial walls and clogs the bronchioles. Exacerbating this, many ciliated columnar cells are replaced by goblet cells in response to the chronic irritation. Therefore the excessive mucus is also less able to be cleared from the lungs. Hence, the use of expectorants is emphasised in the treatment of chronic bronchitis, despite the fact that an easily productive cough can be a feature of this disease. (In some patients sputum may be scanty and tenacious, which also requires treatment with expectorants.)
• Bronchial irritation must be avoided. Giving up smoking and a change in occupation or climate may be necessary. Mucus-producing foods such as dairy products and bananas should be reduced
• Any chronic infection should be treated and acute infections prevented by immune-enhancing herbs, especially Echinacea root and Astragalus (discontinue Astragalus during acute febrile infections). The role here of Panax ginseng has been supported in at least one clinical trial.27 Many chronic bronchitis patients are constitutionally cold, so the cold herbs Picrorrhiza and Andrographis are best avoided. Heating herbs such as cinnamon may be helpful and could possibly be used in conjunction with these cold herbs
• Expectorant herbs, such as Inula helenium, Thymus vulgaris, Polygala and other saponin-containing herbs, Foeniculum (fennel), Pimpinella (aniseed) and Marrubium (white horehound) can be prescribed throughout the course of the disorder. The diffusive stimulant properties of Zingiber will potentiate the activity of expectorants
• Respiratory antiseptic herbs that also have expectorant or mucolytic properties are particularly indicated, such as Inula helenium, Thymus vulgaris and Allium sativum
• Since the goblet cells are oversecreting, anticatarrhal herbs such as Verbascum, Plantago lanceolata and Hydrastis can help to reduce this excessive secretion
• If there is an unproductive cough at night, a separate formula containing demulcents such as Althaea glycetract and Glycyrrhiza, and antitussives such as Glycyrrhiza and Bupleurum, may be prescribed (see below)
• Inhalation of peppermint and eucalyptus oils combined can help loosen mucus and dilate airways to make breathing easier
• Bronchodilating herbs such as Coleus and Lobelia may be helpful. Ephedra should probably be avoided. Those with expectorant activity such as Grindelia can also be selected
• Since chronic inflammation is present, anti-inflammatory herbs such as Glycyrrhiza, Bupleurum and Rehmannia will be of value, as well as omega-3 fatty acids
• Support for the heart and general circulation with Crataegus and Ginkgo may be required.
The following demulcent formula can also be used to relieve an irritable cough:
Althaea officinalis glycetract | 1:5 | 80 mL |
Glycyrrhiza glabra (high in glycyrrhizin) | 1:1 | 20 mL |
total | 100 mL |
Dose: 4 mL sipped undiluted (that is no water is added) as required up to 6 times a day.
Case history
A male patient, 66 years, has received herbal treatment for chronic bronchitis for 7 years. During this time there has been considerable improvement in the patient’s condition and friends often now comment on how well he looks. The frequency of acute episodes has substantially reduced and his lung function parameters have improved. Although treatment varied over this time period, a representative herbal treatment is as follows.
Echinacea angustifolia/purpurea root | 1:2 | 45 mL |
Arctium lappa | 1:2 | 15 mL |
Achillea millefolium | 1:2 | 20 mL |
Withania somnifera | 1:2 | 20 mL |
total | 100 mL |
Dose: 5 mL with water three times a day.
Glycyrrhiza glabra | 1:1 | 15 mL |
Inula helenium | 1:2 | 20 mL |
Zingiber officinale | 1:2 | 10 mL |
Foeniculum vulgare | 1:2 | 15 mL |
Thymus vulgaris | 1:2 | 20 mL |
Grindelia camporum | 1:2 | 20 mL |
total | 100 mL |
‘Bronchiectasis’ describes an abnormal dilatation of the bronchi that becomes a focus for chronic infection. In most cases it develops as a complication of a severe bacterial infection and then follows a chronic course. Clinical features include chronic cough, often with copious purulent sputum, and febrile episodes with malaise and night sweats that can last from a few days to weeks, and sometimes haemoptysis. The disorder can be debilitating. Although continual use of antibiotics is inadvisable, patients can often receive this regime.
Essential aspects of the treatment of bronchiectasis are as follows:
• Immune-enhancing herbs such as Echinacea root, Andrographis and Astragalus
• Respiratory antiseptic herbs such as Inula helenium, Thymus vulgaris and Allium sativum
• Diaphoretics such as Asclepias tuberosa (pleurisy root) during the febrile episodes
• Tonics such as Panax, Rhodiola, Eleutherococcus and/or Withania if debility is present
• Anticatarrhal herbs, including Verbascum, Plantago lanceolata and Hydrastis
• Expectorant herbs such as Inula helenium, Thymus vulgaris, Polygala and other saponin-containing herbs, Foeniculum (fennel), Pimpinella (aniseed) and Marrubium (white horehound)
• Note that Astragalus, Panax and Eleutherococcus should be discontinued during any acute febrile phases.
Echinacea purpurea/angustifolia root | 1:2 | 40 mL |
Inula helenium | 1:2 | 25 mL |
Glycyrrhiza glabra (high in glycyrrhizin) | 1:1 | 15 mL |
Hydrastis canadensis | 1:3 | 30 mL |
total | 110 mL |
Dose: 8 mL with water twice daily.
Case history
A male patient, 59 years, with bronchiectasis. He was initially coughing up an egg cup of sputum every morning and experiencing occasional febrile episodes and acute viral infections. This patient has now been maintained on phytotherapy for more than 15 years. Apart from the occasional winter respiratory infection he remains well. His sputum production is minimal and he freely claims that herbs have ‘kept me alive’.
• Herbal treatment consisted of the following: Echinacea purpurea/angustifolia root tablets (1.275 g), two tablets one to two times daily. The Echinacea liquid disagreed with this patient, hence the tablets. The higher dose is taken during febrile episodes and acute infections.
Aesculus hippocastanum | 1:2 | 15 mL |
Foeniculum vulgare | 1:2 | 10 mL |
Thymus vulgaris | 1:2 | 30 mL |
Astragalus membranaceus | 1:2 | 25 mL |
Inula helenium | 1:2 | 20 mL |
total | 100 mL |
The Aesculus was mainly for circulatory problems but it also has expectorant properties due to its saponin content.
In terms of phytotherapy, asthma is probably the most complex of the respiratory disorders. The successful management of asthma hence embodies most of the principles already discussed. Asthma can be defined as the occurrence of dyspnoeic bronchospasmodic crises linked to an airways hyper-responsiveness (AHR). Like autoimmune disease it is a chronic disturbance of immunological function that can be controlled to some extent, but not eradicated by modern drug therapy. In other words asthma is not just the attacks (crises); it is a chronic disturbance of the immune system with the attacks being the ‘tip of the iceberg’. Hence any treatment aimed only at relaxing airways and relieving symptoms, be it orthodox or herbal, is superficial and will not change the chronicity of the disease.
Recent research has identified many factors that contribute to the aetiology and morbidity of asthma. Traditional herbal medicine also recognises the role of inefficient digestion, poor immunity, stress, diet and unhealthy mucous membranes in the development of the disease. In order to treat asthma more effectively with phytotherapy, it is necessary to have an understanding of the causative and sustaining factors contributing to the condition. For each individual it is likely that the disease process has been precipitated by a unique and complex interaction of contributive events. A multi-factorial model that allows the individualisation of the patient, yet at the same time incorporates the most likely factors operating in asthma, is discussed below. This in turn requires the synthesis of traditional herbal understanding with the latest research findings, which is fundamental to the practice of modern phytotherapy.
Asthma can be classified as extrinsic (allergic asthma) or intrinsic asthma. Although there has been some confusion with the terms, and some medical scientists feel that the classification is meaningless,28 the differentiation is quite clear. Patients with extrinsic asthma comprise the majority of cases and exhibit a positive skin test to common aeroallergens and foods. Serum IgE levels are usually raised. However, extrinsic asthmatics can still be exacerbated by non-specific stimuli such as cold air and exercise. Intrinsic asthmatics have negative skin tests, and chronic infection and other factors are thought to play a role in the disease process. Intrinsic asthma is usually later in onset and more severe.29 Aspirin-sensitive asthma (ASA) is a form of intrinsic asthma. Both types of asthma show an increased family occurrence.30
Asthmatic lungs are characterised by epithelial cell loss, goblet cell hyperplasia, increased collagen deposition, mast cell degranulation and inflammatory cell infiltration.31 Asthma is now primarily classified as an inflammatory disorder. The desquamation allows allergens to penetrate more easily and exposes irritant receptors.
There has been an increased understanding over the past two decades that asthma is a chronic, immunologically mediated condition with a disturbance of the normal airway repair mechanism, which results in inflammatory changes and airway remodelling.32 The airway inflammation and remodelling together likely explain the clinical manifestations of asthma. The mechanisms by which the external environmental cues, together with the complex genetic actions, propagate the inflammatory process that characterise asthma are beginning to be understood. There is also an evolving awareness of the active participation of structural elements, such as the airway epithelium, airway smooth muscle and endothelium in this process. In tandem with this has come the realisation that inflammatory cells respond in a coordinated, albeit dysfunctional, manner via an array of complex signalling pathways that facilitate communication between these cells; these structural elements within the lung and the bone marrow serve as reservoirs for and the source of inflammatory cells and their precursors. Although often viewed as separate mechanistic entities, innate and acquired immunity often overlap in the propagation of the asthmatic response.32
Classically, asthma, specifically allergic asthma, has been attributed to a hyperactive Th2 cell immune response. However, the Th2 cell-mediated inflammation model has failed to adequately explain many of the clinical and molecular aspects of asthma.33 In addition, the outcomes of Th2-targeted therapeutic trials have been disappointing. Thus, asthma is now believed to be a complex and heterogeneous disorder, with several molecular mechanisms underlying the airway inflammation and AHR that is associated with it. The original classification of Th1 and Th2 pathways has recently been expanded to include additional effector Th cell subsets. These include Th17, Th9 and Treg cells. Emerging data highlight the involvement of these new T helper cell subsets in the initiation and augmentation of airway inflammation and asthmatic responses.33
That regulatory T cells (Tregs) have a crucial role in controlling allergic diseases such as asthma is now undisputed. The cytokines most commonly implicated in Treg-mediated suppression of allergic asthma are transforming growth factor-beta (TGF-beta) and interleukin (IL)-10. In addition to naturally occurring Tregs, adaptive Tregs, induced in response to foreign antigens, have been shown in recent studies. The concept of inducible/adaptive Tregs (iTregs) has considerable significance in preventing asthma, if such cells are generated early enough in life.34
Other inflammatory cells implicated in asthma include natural killer T cells, although their role is controversial,35,36 mast cells, neutrophils and eosinophils.37 Platelets and endothelial cells also play a role.
As touched on above, some experts are arguing for a re-evaluation of the therapeutic implications informed by a pathophysiological understanding of asthma. A case is made that asthma has its origins in the airways themselves, involving defective structural and functional behaviour of the epithelium in relation to environmental insults, with wall thickening.38 Specifically, a defect in barrier function and an impaired innate immune response to viral infection may provide the substrate upon which allergic sensitisation takes place. Once sensitised, the repeated allergen exposure will lead to disease persistence. These mechanisms could also be used to explain the observed airway wall remodelling and the susceptibility of the asthmatic lung to exacerbations provoked by respiratory viruses, air pollution episodes and exposure to biologically active allergens. It seems that the problem lies in placing allergy at the centre of disease pathogenesis, when in practice other environmental factors may be equally if not more important in the induction and then progression of asthma. Instead a defect of epithelial barrier function exists that, as in atopic dermatitis, allows greater access of environmental allergens, microorganisms, and toxicants to the airway tissue. Evidence indeed indicates that both the physical and functional barrier of the airway epithelium is defective in asthma with disrupted tight junctions, reduced antioxidant activity, and impaired innate immunity. Viewing asthma primarily as an epithelial disease, with the conceptual adoption of a chronic wound scenario, also provides a route to understand the observed airway wall remodelling and the varying asthma phenotypes over its life course.39
A host of inflammatory mediators have been identified in the pathophysiology of asthma. However some mediators may be more involved in triggering the inflammatory process than others. In this context, important mediators are the Th2 cytokines and probably histamine, platelet activating factor (PAF), major basic protein, leukotrienes especially (leukotriene B4)40 and to a lesser extent prostaglandins.37 Patients with ASA have increased PAF responsiveness, reduced prostaglandin levels and increased leukotrienes compared with normal controls.41,42 TGF-beta is a key player in airway remodelling.
The host of inflammatory cells and mediators involved in the pathogenic process means that treatment directed at a single mediator or cell is unlikely to be successful. A multi-faceted approach to treatment is required. This is compatible with herbal therapy, which has traditionally used combinations of plants to treat diseases.
The above considerations also explain the current preference in conventional medicine for steroid use in asthma. These drugs have a broad suppressing effect on many inflammatory mechanisms. In this context the ‘magic bullet’ is more like an ordinary shotgun.
Differentiation should be made between the causes that initiate or sustain the underlying condition, which are probably factors that result in injury to the lining of the lungs, and the triggers that precipitate the asthmatic attack. While avoidance of the latter group is of course important, it is only attention to the former that will reduce the progression of the disease. There is no better illustration of this issue than the subject of dairy products. Traditional knowledge suggests that consumption of dairy products can lead to a state of unhealthy mucous membranes in sensitive patients. However, these patients may not give a positive skin test to dairy products, and these products may not provoke an acute asthmatic attack. In the classical sense there is no allergy to dairy products. Yet the avoidance of this food group will, in time, give appropriate patients considerable relief from their asthmatic condition. Key factors amenable to treatment are reviewed below.
The most significant allergen in the long-term development of asthma is now considered to be the house dust mite. However, this does not necessarily mean that the degree of house dust mite exposure will correlate with the day-to-day severity of asthma. This is because sensitivity to the house dust mite feeds the underlying pathological process. Unfortunately, chemical and physical methods aimed at reducing exposure to house dust mite allergens have yielded disappointing results.43
Other common factors involved in asthma development may include cats, cockroaches, grass pollens and molds, but the situation is complex, as for dust mite.44 Association with severe asthma in children was seen between non-feather bedding, especially foam pillows and the current ownership of furry pets, or ownership at birth.45 A Finnish study of school children aged 7 to 13 found that moisture and mold problems in the school building were linked to respiratory infections and asthma.46
Of course, all the above allergens can trigger an asthma attack, as can many foods, especially dairy products, eggs and nuts. Dust mite contamination of wheat flour caused anaphylactic reactions and cooking had no effect. It was suggested that flour be stored in the refrigerator.47 Royal jelly should be used cautiously as it is now a well-known trigger of asthma attacks.
Maternal or parental smoking has been linked to asthma incidence and severity.48 Air pollution parameters such as NO2, ozone and particulates have also been associated with the incidence of asthma.49
Exposure to dust, irritants and allergens at the workplace can also cause asthma. Usually withdrawal from the irritant or allergen results in remission, but in some cases where exposure is prolonged the asthma becomes self-sustaining despite such withdrawal.
Sinusitis has been associated with asthma in several studies,50,51 although this has received less attention recently. This is not considered to be due to aspiration of sinus contents.52 In one study 79% of asthma cases had chronic rhinitis or rhinosinusitis.53 In 69% of cases the nasal symptoms coincided with or preceded the onset of asthma. In 59% of associated cases, nasal symptoms coincided with acute asthmatic episodes. Treatment of the nasal condition improved the asthma. The link between sinusitis and asthma is strongest in patients with intrinsic asthma. Evidence supports the concept that rhinosinusitis and asthma may be the expression of an inflammatory process that appears in different sites of the respiratory tract at different times.54
A number of researchers in the 1930s found a high incidence of hypochlorhydria in asthmatic patients.55 In these studies the test meal method was used. This method is now considered inappropriate for the assessment of histological hypochlorhydria. However it does assess for functional hypochlorhydria, that is a deficiency of vagal stimulation of acid production. Hydrochloric acid therapy improved the asthma.55 Since this kind of gastric deficiency is due to deficient vagal output, the use of bitter herbs that act through a vagal reflex to increase gastric digestion is indicated (see Chapter 2).
Gastro-oesophageal reflux (GOR) has been linked to asthma in several studies. In fact there is evidence that GOR is an important aetiological factor for some asthmatics. Monitoring of oesophageal pH revealed GOR in seven out of nine patients with persistent asthma.56 In another study 61% of patients with intrinsic asthma exhibited GOR.57 From studies on children it was concluded that asthma symptoms were more often elicited by exposure of the distal oesophagus to gastric acid, possibly by a vagal reflex, than by aspiration of gastric juice.58 However, other studies have implicated the importance of aspiration.59,60 In support of the reflex hypothesis, subjects with GOR (but not asthma) showed a significantly greater bronchial reactivity to histamine than normal matched controls.61
Treatment of GOR by surgery or drugs can result in improvement or cure of asthma, although results are mixed and suggest that targetting of individual patients is necessary.62 (Also see Chapter 2, under Mucilages.)
Particular foods are well-known causes of asthma attacks. However, the contribution of diet to the underlying pathophysiological processes of asthma is not well studied. It has been postulated that dietary changes may have contributed to the rise in asthma mortality.63 In particular, increased consumption of polyunsaturated fatty acids has resulted in the doubling from 8% to 15% of the linoleic content of body fat.63 Such a change could be regarded as pro-inflammatory.
Coffee consumption was found to be inversely correlated to the prevalence of bronchial asthma in an Italian study.64 Epidemiological studies found that consumption of oily fish may protect against asthma in childhood65 and adults,66 and a connection between low magnesium intake and increased asthma risk has also been suggested.67 Consumption of apples (five per week) was found to improve lung function.68 This benefit was attributed to the flavonoids found in apples.
A systematic review and meta-analysis found weak but supportive protective evidence with respect to dietary vitamins A, D and E, zinc, fruits and vegetables and a Mediterranean diet.69
Viral infections are known to exacerbate asthma. Viral infection in the upper airways frequently triggers deterioration in airways hyperreactivity in asthmatics.70 Most hospital admissions for asthma occur over the winter months and soon after the start of school terms.70 Viral infections also worsen asthma in adults.71,72
There is also some evidence to suggest that viral infections may also contribute to the development of asthma, especially in children. About 92% of children hospitalised with respiratory syncytial virus (RSV) bronchiolitis in the first year of life subsequently developed symptoms suggestive of asthma within 5 years.73 Of this group, 71% had clinical evidence of asthma.73 Recurrent upper respiratory tract infections are associated with asthma risk in children74 and 37% of children with viral lower respiratory tract infections in infancy subsequently developed asthma.75 With the development of molecular diagnostics, human rhinovirus wheezing illnesses have been recognised more recently as a stronger predictor of school-age asthma than RSV.76
In contrast, bacterial infection has been linked to adult-onset asthma. The first study linking repeated or prolonged exposure to Chlamydia pneumoniae with wheezing, asthmatic bronchitis and asthma was published in 1991.77 Patients with evidence of C. pneumoniae exposure comprised 81% of 26 patients with asthmatic bronchitis, 100% of asthmatic bronchitics 40 years and older, and 8 out of 10 patients with asthma. However, findings from later studies have been inconsistent.78 Associations between Mycoplasma species and chronic asthma are relatively well-established.78
A group of 12 adult patients with asthma and chronic fungal skin infection were found to have hypersensitivity to Trichophyton spp.79 Several patients had many of the features of late-onset intrinsic asthma. A Russian study in children with bronchial asthma living near a microbiological factory found that most were hypersensitive to Candida.80 Asthma has also been associated with parasitic infestation with Strongyloides stercoralis.81
Regional sales of table salt in England and Wales are strongly correlated with deaths from asthma in men and children.82 A study of 138 men found a close relation between AHR and 24 h urinary sodium excretion.83 Other studies have yielded conflicting results. A large randomised controlled trial of slow sodium supplementation showed an increase in AHR in men, but not women,84 and a low salt intake was correlated with improved asthma in men.85 Several mechanisms for this association have been postulated, such as an increase in circulating Na,K-ATPase inhibitors or a decrease in catecholamine concentration.86 Data supporting dietary salt restriction for reducing AHR in asthmatics are encouraging.87
Exercise-induced asthma may be related to dehydration of the intrathoracic airways during hyperpnoea.88 A high salt intake may interfere with rehydration of the airways. Mouth breathing as a result of sinusitis may also cause airway dehydration.
Glucocorticoid insufficiency related to various adrenal and extra-adrenal mechanisms has been associated with asthma in a Russian study.89 Reduced nocturnal catecholamine and cortisol levels, which are a natural part of circadian rhythm, may be linked to the nocturnal exacerbation commonly associated with asthma.90 Stress-induced corticosteroid resistance or insensitivity in asthma is receiving research attention,91 as is hyporesponsiveness of the HPA (hypothalamic-pituitary- adrenal) axis (see also below).92
It was postulated that an increase in brain norepinephrine can reflect depression of the HPA axis.93 In asthmatic children such an increase was found compared with controls.93
Premenstrual asthma has been observed, which was improved by progesterone injection.94 Dynamic changes in hormone concentrations during the perimenstrual period are thought to be responsible for the rise in emergency admissions of asthmatic women at this time. Hormonal variation may prove to be a significant and independent risk factor for acute exacerbations of asthma.95 Although the observed 4-fold increase in emergency admissions suggested that hormonal variation may influence the timing of an asthma attack, the severity of symptoms was no worse than that among women who presented at any other time in their menstrual cycle.
Low-income patients were more likely to report exacerbation of asthma when upset or anxious.96 Parents of children who developed asthma were more likely to have problems in coping and parenting.97
Stress and associated muscular tension might influence lung function. One study suggested that an intrinsic impairment of the ability of inspiration to stretch airway smooth muscle is a major feature of asthma.98 In other words, defective deep breathing could be a factor in airway narrowing. This would suggest a role for relaxation and breathing techniques in asthma.
The role of oxidative stress in asthma is gaining increasing research attention.99 Activation of the Nrf2/ARE pathway could prove to be of therapeutic benefit.100 Patients with acute asthma had decreased antiperoxide plasma activity compared with normal controls.101 Moreover the severity of the asthma was inversely associated with the above parameter. In patients with steroid-dependent asthma the free radical process was more intensive.101 Low selenium concentrations in whole blood have been correlated to increased asthma risk in New Zealand.102
Floyer in his Treatize of the Asthma published in 1698 wrote:
Some writers … have observed the hypochondriac symptoms in the stomach and conclude the asthma … wants digestives …. It is commonly observed that fullness of diet, and all debauches render the fits most severe, and a temperate diet makes the fits more easy …. The defect of digestion and mucilaginous slime in the stomach are very obvious and observed by writers ….
… the precursory symptoms are connected with the stomach and consist of loss of appetite, flatulence, costiveness and certain peculiar uneasy sensations in the epigastrium; but here I think we have something more than mere premonitory signs; I think the relation of these symptoms to the spasm which follows is often that of cause and effect.
Mucus secreted by mucous membranes (MM) is normal and has many important physiological functions. When MM become unhealthy, the nature and the quantity of the mucus changes. This can be referred to as a catarrhal condition. The degree of catarrhal congestion of the lungs can vary in asthma, and is best assessed by auscultation and case history. The association of chronic sinusitis with asthma is indicative of unhealthy MM. Despite the excessive mucus, catarrhal MM are thought to provide less protection than healthy MM, and in the case of asthma render the lungs more prone to damaging environmental factors such as allergens and pathogens. This traditional concept ties in well with the newer understanding of asthma as primarily a defect of airway epithelium, as described above.
Diet is a significant factor in causing a catarrhal state of the respiratory MM. Excessive protein, refined carbohydrate or salt consumption can lead to excessive and unhealthy mucus production. In some individuals, particular food groups especially dairy and/or wheat can also contribute to this process.
Catarrhal MM can also be regarded as a vicarious elimination due to inefficient detoxification and elimination in the body. Hence in traditional terms the detoxifying and eliminative processes need to be supported and stimulated.
Traditionally asthma has been regarded as imbalance in the autonomic nervous system. Stress and nervous anxiety contribute to this imbalance which may also cause muscular tension in the diaphragm and disturb the rhythmic nature of the breathing apparatus.It has been postulated that asthma results from a disturbance of the rhythmic activity of the respiratory centre in the brain.103 This disorder is then reflected in the airways and the respiratory muscles through their respective innervations to cause a subclinical template of asthma. This rhythmic disturbance is reflected in the EEG of asthmatic patients, which generally contain certain abnormalities.103
Treatment goals will obviously vary according to the needs of the individual case at the particular time of treatment. However, based on the above considerations they can be divided into two main categories: symptomatic treatment and treatment of the underlying issues (Table 9.1). The required actions related to the specific treatment goals and relevant herbs are also provided. Some treatment goals, such as resolving sinusitis, are complete therapeutic subjects in themselves and are covered elsewhere in this chapter.
This approach is informed by modern research and contrasts with the traditional approach that merely focussed on bronchodilator and expectorant activities (Table 9.2).
Table 9.2 Major herbs for asthma according to the British Herbal Pharmacopoeia 1983
Herb | Action |
---|---|
Datura | Spasmolytic |
Drosera | Bronchodilator, expectorant |
Ephedra | Bronchodilator (antiallergic) |
Euphorbia | Spasmolytic, expectorant |
Grindelia | Antispasmodic, expectorant |
Lobelia | Spasmolytic, expectorant |
Some plants have specialised effects on the inflammatory or allergic mechanisms known to occur in asthma. Since some of these effects have only recently been discovered or studied, a discussion of the research findings follows.
Cepaenes and thiosulfinates from Allium cepa (onion) are dual inhibitors of arachidonic acid metabolism, as are the gingerols from Zingiber officinale (ginger). See also the monograph on turmeric regarding its relevant anti-inflammatory and antiasthmatic activities. Boswellia has been successfully trialled in asthma on the basis of its anti-inflammatory activity (see monograph).
Isothiocyanates, cepaenes and thiosulfinates from Allium cepa have demonstrated an asthma-protective effect in animal models. The thiosulfinates counter platelet activating factor (PAF) and histamine-induced bronchoconstriction. In a human experiment, allergen-induced asthma attacks were almost completely inhibited by an Allium cepa extract.104
In vitro studies in the late 1980s discovered that the ginkgolides from the Ginkgo biloba leaf are potent and specific PAF antagonists (see monograph). In vivo animal studies (oral and injected routes) confirmed this activity.105 Ginkgo and ginkgolides have also shown some beneficial clinical activity in asthma (see monograph).
Tylophora indica (Tylophora asthmatica) is a potent antiasthmatic herb that depresses cell-mediated immunity.106 It also stimulates the adrenal cortex, increasing plasma steroid levels and antagonising steroid-induced suppression of adrenal activity.107 Several poorly designed clinical trials using Tylophora have shown benefits.108
Flavonoids from Scutellaria baicalensis have marked antiallergic activity. Baicalin and baicalein demonstrated antiallergic and antiasthmatic activity in several animal models.109 For example oral administration of baicalin to egg-white-sensitised guinea pigs protected them against allergic reaction from re-inspiration of the antigen. Both compounds suppressed cutaneous allergy in guinea pigs.109 A soluble derivative of baicalein was antiallergic after oral administration110 and demonstrated more extensive antiallergic activity than sodium cromoglycate in vitro.111 Other flavonoids from Baical skullcap were active in inhibiting the histamine release from rat peritoneal mast cells in vitro,112 and baicalein inhibited basophil histamine content and growth in vitro.113
Saiboku-To (TJ-96) is a Kampo medicine comprising 10 herbs including Baical skullcap. It has been used in Japan for glucocorticoid-dependent asthmatic patients with the aim of reducing the dose of administered glucocorticoids. The antiallergic action of Saiboku-To is based on the suppression of type I and IV allergic reaction, which has been confirmed in animal studies.114
Albizia lebbek has mast cell stabilising activity.115 Its antiallergic effects may also be mediated by suppression of lymphocyte function.116
Adhatoda vasica is a small evergreen, subherbaceous bush that grows on the plains of India, in the lower Himalayan ranges and in Sri Lanka, Burma and Malaysia. Adhatoda leaf has been used extensively in the Ayurvedic system for over 2000 years.117 It has antiasthmatic, bronchodilating and expectorant activities and is traditionally used for the treatment of asthma, bronchitis cough and common cold.118 In the World Health Organization publication The Use of Traditional Medicine in Primary Health Care: A Manual for Health Workers in South-East Asia, Adhatoda was said to facilitate breathing and to make sputum more fluid, thereby facilitating its removal. Adhatoda preparations are recommended for long-term use in adults and children.119 However, it is contraindicated during pregnancy.
Key constituents of Adhatoda leaf are the quinazoline alkaloids (0.5% to 2%). The major alkaloid is vasicine present at levels of 45% to 95%. Minor alkaloids include vasicinine, vasicinone, oxyvasicinine, deoxyvasicine, deoxyvasicinone and vasicinol.120,121 The drug bromhexine was developed from vasicine in Europe prior to the 1960s and is still used as an aid to expectoration by reducing the viscosity of secretions.122 Oral administration of a mixture of vasicine and vasicinone (25 mg, three times per day) showed good bronchodilating activity in asthma patients. Seventy per cent demonstrated clinical improvement and improvement in spirometry.123
Uncontrolled clinical trials conducted in India as early as 1925 suggested that Adhatoda had an expectorant action. In acute bronchitis Adhatoda provided relief, especially where the sputum was thick and tenacious. In patients with chronic bronchitis cough was relieved and the sputum thinned, which facilitated removal. Mild relief was achieved for asthma.118
There are approximately 40 to 60 species of Grindelia native to temperate, mostly arid and semi-arid regions of North and South America. Species of Grindelia (commonly called gumweeds or gumplant) are not well differentiated and the taxonomy of the genus is still poorly understood. The resins produced by Grindelia consist mostly of labdane-type diterpenoid resin acids, similar in chemistry and physical properties to those obtained from pine trees. Resins from various species of Grindelia have been patented for use in adhesives, rubber, coatings and textiles.124
Several species of Grindelia are used in phytotherapy including Grindelia camporum, G. robusta, G. squarrosa and G. humilis. Constituents of the medicinal Grindelia spp. include the resin together with phenolic acids, flavonoids, an essential oil and small amounts of saponins.125
Grindelia is an expectorant herb with bronchospasmolytic activity. It is traditionally recommended for the treatment of spasmodic respiratory conditions such as asthma and bronchitis. The British Herbal Pharmacopoeia 1983 lists the specific indication as bronchial asthma with tachycardia.126 Eclectic physicians also utilised Grindelia for asthma.127
The Chinese herb Sophora flavescens, both on its own and in a formulation, has yielded promising results in asthma management. Its pharmacological properties include diuretic, antiviral, antitumour, sedative and anti-inflammatory activities. The main active components are matrine-type alkaloids, particularly matrine and oxymatrine.128 It has been suggested that the Sophora alkaloids can act as modulators of cell membrane excitability. This is based on its CNS effects, anti-arrhythmic activity and inhibition of glutamate-induced responses.128 On the hypothesis that an excitatory modulator (especially in the context of glutamate responses) may be beneficial in asthma, an open trial of Sophora in refractory asthma was initiated.128
From February 1997 to December 2005, 14 patients with moderate to severe asthma (six men and eight women) aged 22 to 70 years were treated. These patients had been diagnosed with asthma by their allergists and had been receiving medication for asthma for 3 to 6 years. Despite years of moderate to high doses of inhaled corticosteroids and beta-2 agonists, they still suffered episodes of dyspnoea, expectoration, coughing, wheezing or chest tightness more than two times a week and waking up at night with asthma symptoms more than two times a week.128 The patients were given a dried powder of a hot water extract of S. flavescens root, which contained a high content of matrine and oxymatrine (1.8% to 3.2%). The extract was provided in capsules, with a dose equal to 4 g of dried root, three times daily for 3 months and two times daily for 6 months and once daily for 27 months thereafter. Since the study was open, non-randomised and selective, the results below are summarised based on the records of the diary card of symptoms, PEF (peak expiratory flow), medication use and quality of life.128
After 4 weeks, the daytime asthma symptoms were reduced by 78%, and the night-time symptoms by 75%. Beta-2 agonist dose was reduced by 72% and the dose of corticosteroid inhaler reduced by 45%. The mean PEF rate improved by 12%. Two patients had remarkable improvements of eczema symptoms. No side effects were observed.128 At 1 year, the daytime symptoms of asthma reduced by 94% and night-time symptoms by 95%. Beta-2 agonist use was reduced by 95%; corticosteroid inhaler was reduced by 92%. The mean PEF had increased by 18%. After 3 years, the daytime symptoms of asthma were reduced by 97%, night-time symptoms by 98%. The dose of beta-2 agonist was reduced by 97% and no patients inhaled corticosteroids. The mean PEF had increased by 21%. At 3 years, nine of the patients had achieved a symptom-free, medication-free and also an asthma-free condition, meaning they did not develop asthma symptoms when they were exposed to the previous triggers of their asthma attacks. Two of the patients with functional and radiological evidence of emphysema achieved an improvement in both breathing capacity and airway fibrosis (emphysema) to the extent that they were no longer considered to have emphysema. Two patients had complete remission of their eczema.128
Despite these striking results, they must be viewed with caution since this was an open label trial and there was no placebo group. Hence, it is encouraging to learn that Sophora in conjunction with two other traditional Chinese herbs (Glycyrrhiza uralensis (licorice) and Ganoderma lucidum) was found to be active in a controlled trial.129 The efficacy and tolerability of this formula was investigated in 91 patients with moderate to severe asthma in a double blind, randomised trial. The herbal treatment was compared with oral prednisone therapy.129
Patients in the herbal group received oral capsules (3.6 g/day of the mixture) and placebo tablets similar in appearance to prednisone. Those in the prednisone group received oral prednisone tablets (20 mg/day in the morning) and ‘herbal placebo capsules’, for 4 weeks. Treatment was administered daily over a period of 4 weeks. No medications other than rescue beta-2 agonists were allowed. This study found that post-treatment lung function (FEV1 and PEF values) was significantly improved in both groups. The improvement was slightly but significantly greater in the prednisone group (p<0.05). There was a significant and a similar degree of reduction in clinical symptom scores in both treated groups.129
Of interest, the Th2 cytokines IL-5 and IL-13 were significantly reduced in both treated groups (p<0.001 for each). Strikingly, serum interferon (IFN)-gamma and cortisol levels were significantly decreased in the prednisone group (p<0.001), but significantly increased in the herbal group (p<0.001). In addition, the herbal treatment had no significant effect on body weight (increases in body weight post-therapy, 2.8 kg in the prednisone group versus 0.8 kg in the herbal group). No significant side effects were observed.
Asthma is a deep-seated protracted condition that requires herbal treatment in pharmacological doses. Hence a high dosage protocol is proposed. Based on the treatment goals outlined above it is suggested that two formulations, each of four to six herbs, are developed for the individual patient, or otherwise one formulation and a herbal tablet or capsule.
One should be a long-term treatment aimed at treating the underlying factors behind the asthmatic condition. The second can be aimed at the symptoms and sustaining causes. (A third formula could be developed which is only to be taken to alleviate acute attacks, but these days most patients will resort to a bronchodilating drug in these circumstances.)
The herbs in the two formulations should be chosen so that there is as much overlap of the required actions as possible. This reduces the number of herbs needed to give a broad range of required actions (as informed by Table 9.1). For example:
The adult patient is then prescribed an 8 mL dose of each formula two to three times a day. Dosages are adjusted for children based on their body weight.
The treatment should be varied over time depending on the patient’s response. Also not every factor can necessarily be treated at the one time, so particular treatment goals may need to be changed from time to time. This should be a dynamic and interactive approach. The following case histories illustrate some aspects of this strategy.
Case history
The patient, 16-year-old teenage girl, had had asthma since the age of 6. She had been hospitalised several times, including recently. She had marked upper respiratory allergy and ‘had a constant cold all last year’. Medication was inhaled bronchodilators and steroids. The patient was advised to eliminate all dairy products from her diet.
The following herbal tablets were prescribed:
• A tablet containing Echinacea angustifolia root 500 mg, Ocimum tenuiflorum 500 mg, Andrographis paniculata 1000 mg and Ocimum tenuiflorum leaf essential oil 10 mg. Dose 4/day
• A tablet containing Boswellia serrata 1.9 g, Apium graveolens 1000 mg, Zingiber officinale 300 mg and Curcuma longa 2 g. Dose 2/day
• A tablet containing Echinacea angustifolia root 600 mg and Echinacea purpurea root 675 mg. Dose 1/day
• A tablet containing Scutellaria baicalensis 800 mg, Albizia lebbek 800 mg and Tanacetum parthenium 50 mg. Dose 2/day.
Over a 6-month treatment period the patient’s condition improved dramatically. The need for inhaled conventional drugs was reduced to almost zero, her sinuses cleared and there was a considerable enhancement of general well-being.
The following case illustrates how herbal tablets can be effectively used to manage asthma in patients who have difficulty negotiating tinctures and liquid extracts. Here the tablets were largely aimed at controlling inflammation and allergy, and supporting immune function.
Case history
A 75-year-old female patient developed late onset asthma following a bout of lower respiratory infections and was prescribed prednisone by her medical doctor (now stopped). She also had pronounced sinus congestion and was under stress because of selling and moving house.
The following herbal treatments were instituted:
Euphrasia officinalis | 1:2 | 25 mL |
Ginkgo biloba (standardised extract) | 2:1 | 25 mL |
Echinacea angustifolia/purpurea root | 1:2 | 25 mL |
Eleutherococcus senticosus | 1:2 | 25 mL |
total | 100 mL |
Dose: 8 mL with water twice a day
Three herbal tablets per day containing: Scutellaria baicalensis 500 mg, Adhatoda vasica 750 mg, Grindelia camporum 300 mg, Curcuma longa 1000 mg, Ginkgo biloba leaf 1000 mg and Foeniculum vulgare essential oil 5 mg.
After 4 weeks, the patient reported that her asthma had substantially improved. This improvement was also sustained by the next consultation 4 weeks later. The patient was then subsequently maintained with just the herbal tablets, which according to her reports provided substantial relief for her asthma on an ongoing basis.
References
1. Chen S. Natural products triggering biological targets – a review of the anti-inflammatory phytochemicals targeting the arachidonic acid pathway in allergy asthma and rheumatoid arthritis. Curr Drug Targets. 2011;12(3):288–301.
2. Passalacqua G, Bousquet PJ, Carlsen KH, et al. ARIA update: 1. Systematic review of complementary and alternative medicine for rhinitis and asthma. J Allergy Clin Immunol. 2006;117:1054–1062.
3. Gonzalez H, Ahmed T. Suppression of gastric H2-receptor mediated function in patients with bronchial asthma and ragweed allergy. Chest. 1986;89(4):491–496.
4. Minton NA. Volunteer models for predicting antiemetic activity of 5-HT3-receptor antagonists. Br J Clin Pharmacol. 1994;37(6):525–530.
5. Muller-Limmroth W, Frohlich HH. Effect of various phytotherapeutic expectorants on mucociliary transport. Fortsch Med. 1980;98(3):95–101.
6. Nosál’ova G, Strapková A, Kardosová A, et al. Antitussive action of extracts and polysaccharides of marsh mallow (Althea officinalis L., var. robusta). Pharmazie. 1992;47(3):224–226.
7. Horwitz R. Controlling asthma: the role of nutrition. Explore. 2005;1(5):393–395.
8. Wilson D, Evans M, Guthrie N, et al. A randomized, double blind, placebo-controlled exploratory study to evaluate the potential of Pycnogenol® for improving allergic rhinitis symptoms. Phytother Res. 2010;24(8):1115–1119.
9. Lau B, Riesen S, Truong K, et al. Pycnogenol as an adjunct in the management of childhood asthma. J Asthma. 2004;41(8):825–832.
10. Giles M, Ulbricht C, Khalsa KPS, et al. Butterbur: an evidence-based systematic review by the Natural Standard Research Collaborative. J Herbal Pharmacother. 2005;5(3):119–143.
11. Schapowal A. Treating intermittent allergic rhinitis: a prospective, randomized, placebo and antihistamine-controlled study of butterbur extract Ze 339. Phytother Res. 2005;19:530–537.
12. Lee K, Carstairs I, Haggart K, et al. Butterbur, a herbal remedy, attenuates adenosine monophosphate induced nasal responsiveness in seasonal allergic rhinitis. Clin Exp Allergy. 2003;33:882–886.
13. Danesch U. Petasites hybridus (butterbur root) extract in the treatment of asthma – an open trial. Altern Med Rev. 2004;9(1):54–62.
14. Agbabiaka TB, Guo R, Ernst E. Pelargonium sidoides for acute bronchitis: A systematic review and meta-analysis. Phytomedicine. 2008;15:378–385.
15. Timmer A, Günther J, Rücker G, et al. Pelargonium sidoides extract for acute respiratory tract infections. Cochrane Database Syst Rev. 3, 2008. CD006323
16. Barak V, Berkenfeld S, Halperin T, Kalickman I. The effect of herbal remedies on the production of human inflammatory and anti-inflammatory cytokines. Isr Med Assoc J. 2002;4:919–921.
17. Guo R, Pittler MH, Ernst E. Herbal medicines for the treatment of allergic rhinitis: a systematic review. Ann Allergy Asthma Immunol. 2007;99(6):483–495.
18. Ernst E. Frankincense: systematic review. Br Med J. 337, 2008. a2813
19. Hofmann D, Hecker M, Volp A. Efficacy of dry extract of ivy leaves in children with bronchial asthma – a review of randomized controlled trials. Phytomedicine. 2003;10:213–220.
20. Kurz H. Antitussiva und Expektoranzien. Stuttgart: Wissenschaftliche Verlagsgesellschaft, 1989.
21. Remberg P, Bjork L, Hedner T, Sterner O. Characteristics, clinical effect profile and tolerability of a nasal spray preparation of Artemisia abrotanum L for allergic rhinitis. Phytomedicine. 2004;11(1):36–42.
22. Eccles R, Morris S, Tolley NS. The effects of nasal anesthesia upon nasal sensation of airflow. Acta Otolaryngol (Stockholm). 1988;106:152–155.
23. Hedayat KM. Essential oil diffusion for the treatment of persistent oxygen dependence in a three-year-old child with restrictive lung disease with respiratory syncytial virus pneumonia. Explore. 2008;4(4):264–266.
24. Dorow P. Welchen Einfluss hat Cineol auf die mukoziliare Clearance? Therapiewoche. 1989;39:2652–2654.
25. Lorenz J, Ferlinz R. Expektoranzien: pathophysiologie und therapie der mukostase. Arzneimitteltherapie. 1985;3:22–27.
26. Kleigman RM, Behrman RE, Jenson HB, et al. Nelson Textbook of Pediatrics, 18th ed. Philadelphia: Saunders Elsevier, 2007.
27. Scaglione K, Weiser M. Effects of the standardised Ginseng extract G115 in patients with chronic bronchitis. Clin Drug Invest. 2001;21(1):41–45.
28. Burrows B, Martinez FD, Halonen M, et al. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med. 1989;320(5):271–277.
29. Ulrik CS, Backer V, Dirksen A. Mortality and decline in lung function in 213 adults with bronchial asthma: a ten-year follow up. J Asthma. 1992;29(1):29–38.
30. Pirson F, Charpin D, Sansonetti M, et al. Is intrinsic asthma a hereditary disease? Allergy. 1991;46(5):367–371.
31. Beasley R, Roche W, Holgate ST. Inflammatory processes in bronchial asthma. Drugs. 1989;37(suppl 1):117–122.
32. Murphy DM, O’Byrne PM. Recent advances in the pathophysiology of asthma. Chest. 2010;137(6):1417–1426.
33. Durrant DM, Metzger DW. Emerging roles of T helper subsets in the pathogenesis of asthma. Immunol Invest. 2010;39(4–5):526–549.
34. Ray A, Khare A, Krishnamoorthy N, et al. Regulatory T cells in many flavors control asthma. Mucosal Immunol. 2010;3(3):216–229.
35. Umetsu DT, Dekruyff RH. Natural killer T cells are important in the pathogenesis of asthma: the many pathways to asthma. J Allergy Clin Immunol. 2010;125(5):975–979.
36. Thomas SY, Chyung YH, Luster AD. Natural killer T cells are not the predominant T cell in asthma and likely modulate, not cause, asthma. J Allergy Clin Immunol. 2010;125(5):980–984.
37. Murdoch JR, Lloyd CM. Chronic inflammation and asthma. Mutat Res. 2010;690(1–2):24–39.
38. Holgate ST, Arshad HS, Roberts GC, et al. A new look at the pathogenesis of asthma. Clin Sci (Lond). 2009;118(7):439–450.
39. Holgate ST, Roberts G, Arshad HS, et al. The role of the airway epithelium and its interaction with environmental factors in asthma pathogenesis. Proc Am Thorac Soc. 2009;6(8):655–659.
40. Hallstrand TS, Henderson WR, Jr. An update on the role of leukotrienes in asthma. Curr Opin Allergy Clin Immunol. 2010;10(1):60–66.
41. Taylor ML, Stewart GA, Thompson PJ. The differential effect of aspirin on human platelet activation in aspirin-sensitive asthmatics and normal subjects. Br J Clin Pharmacol. 1993;35(3):227–234.
42. Yamashita T, Tsuji H, Maeda N, et al. Etiology of nasal polyps associated with aspirin-sensitive asthma. Rhinology Suppl. 1989;8:15–24.
43. Gøtzsche PC, Johansen HK. House dust mite control measures for asthma: systematic review. Allergy. 2008;63(6):646–659.
44. Arshad SH. Does exposure to indoor allergens contribute to the development of asthma and allergy? Curr Allergy Asthma Rep. 2010;10(1):49–55.
45. Strachan DP, Carey IM. Home environment and severe asthma in adolescence: a population based case-control study. BMJ. 1995;311:1053–1056.
46. Taskinen T, Hyvarinen A, Meklin T, et al. Asthma and respiratory infections in school children with special reference to moisture and mold problems in the school. Acta Paediatr. 1999;88:1373–1379.
47. Carpi J. Mite-contaminated foods linked to anaphylaxis. Fam Pract News. May. 1996;1:19.
48. Bakirtas A. Acute effects of passive smoking on asthma in childhood. Inflamm Allergy Drug Targets. 2009;8(5):353–358.
49. Sarnat JA, Holguin F. Asthma and air quality. Curr Opin Pulm Med. 2007;13(1):63–66.
50. Brugman SM, Larsen GL, Henson PM, et al. Increased lower airways responsiveness associated with sinusitis in a rabbit model. Am Rev Respir Dis. 1993;147(2):314–320.
51. Friday GA, Jr., Fireman P. Sinusitis and asthma: clinical and pathogenetic relationships. Clin Chest Med. 1988;9(4):557–565.
52. Bardin PG, Van Heerden BB, Joubert JR. Absence of pulmonary aspiration of sinus contents in patients with asthma and sinusitis. J Allergy Clin Immunol. 1990;86(1):82–88.
53. Jarikre LN, Ogisi FO. Nasal symptoms in bronchial asthma. East Afr Med J. 1990;67(1):9–12.
54. de Benedictis FM, del Giudice MM, Severini S, Bonifazi F. Rhinitis, sinusitis and asthma: one linked airway disease. Paediatr Respir Rev. 2001;2(4):358–364.
55. Bray GW. The hypochlorhydria of asthma of childhood. Q J Med. 1931;24:181–197.
56. Barberio G, Ruggeri C, Pajno GB, et al. Gastro-esophageal reflux and asthma. Clinical experience. Minerva Pediatr. 1989;41(7):363–366.
57. Giudicelli R, Dupin B, Surpas P, et al. Gastroesophageal reflux and respiratory manifestations: diagnostic approach, therapeutic indications and results. Ann Chir. 1990;44(7):552–554.
58. Gustafsson PM, Kjellman NI, Tibbling L. Bronchial asthma and acid reflux into the distal and proximal oesophagus. Arch Dis Child. 1990;65(1):1255–1258.
59. Geller LI, Glinskaia TP, Nikolaeva LI, Petrenko VF. Gastroesophageal reflux and bronchial asthma. Ter Arkh. 1990;62(2):69–72.
60. Donnelly RJ, Berrisford RG, Jack CI, et al. Simultaneous tracheal and esophageal pH monitoring: investigating reflux-associated asthma. Ann Thorac Med. 1993;56(5):1029–1033.
61. Agarwal A, Rishi JP, Gupta AN, Bhandari VM. Histamine bronchoprovocation tests in subjects with gastro-oesophageal reflux disease. J Assoc Physicians India. 1990;38(2):159–161.
62. McCallister JW, Parsons JP, Mastronarde JG. The relationship between gastroesophageal reflux and asthma: an update. Ther Adv Respir Dis. 2011;5(2):143–150.
63. Chang CC, Phinney SD, Halpern GM, Gershwin ME. Asthma mortality: another opinion – is it a matter of life and … bread? J Asthma. 1993;30(2):93–103.
64. Pagano R, Negri E, Decarli A, La Vecchia C. Coffee drinking and prevalence of bronchial asthma. Chest. 1988;94(2):386–389.
65. Hodge J, Salome CM, Peat JK, et al. Consumption of oily fish and childhood asthma risk. MJA. 1996;164:137–140.
66. Laerum BN, Wentzel-Larsen T, Gulsvik A, et al. Relationship of fish and cod oil intake with adult asthma. Clin Exp Allergy. 2007;37(11):1616–1623.
67. Britton J, Pavord I, Richards K, et al. Dietary magnesium, lung function, wheezing, and airway hyperreactivity in a random adult population sample. Lancet. 1994;344(8919):357–362.
68. Stuttaford T. Medical Briefing: Apple of the doctor’s eye. The Times. February. 2000;3:15.
69. Nurmatov U, Devereux G, Sheikh A. Nutrients and foods for the primary prevention of asthma and allergy: systematic review and meta-analysis. J Allergy Clin Immunol. 2011;127(3):724–733. e1–e30
70. Bardin PG, Johnston SL, Pattemore PK. Viruses as precipitants of asthma symptoms. II. Physiology and mechanisms. Clin Exper Allergy. 1992;22(9):809–822.
71. Beasley R, Coleman ED, Hermon Y, et al. Viral respiratory tract infection and exacerbations of asthma in adult patients. Thorax. 1988;43(9):679–683.
72. Kloepfer KM, Gern JE. Virus/allergen interactions and exacerbations of asthma. Immunol Allergy Clin North Am. 2010;30(4):553–563.
73. Sly PD, Hibbert ME. Childhood asthma following hospitalization with acute viral bronchiolitis in infancy. Pediatr Pulmonol. 1989;7(3):153–158.
74. Rylander E, Pershagen G, Eriksson M, Nordvall L. Parental smoking and other risk factors for wheezing bronchitis in children. Eur J Epidemiol. 1993;9(5):517–526.
75. Liu WJ, Lo WS, Hsieh HJ, et al. Increased incidence of asthma and pulmonary dysfunction after severe lower respiratory tract infection in infancy. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi [Acta Paediatr Sin]. 1991;32(6):348–357.
76. Jackson DJ, Lemanske RF, Jr. The role of respiratory virus infections in childhood asthma inception. Immunol Allergy Clin North Am. 2010;30(4):513–522.
77. Hahn DL, Dodge RW, Golubjatnikov R. Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma. JAMA. 1991;266(2):225–230.
78. Guilbert TW, Denlinger LC. Role of infection in the development and exacerbation of asthma. Expert Rev Respir Med. 2010;4(1):71–83.
79. Ward GW, Jr., Karlsson G, Rose G, Platts-Mills TA. Trichophyton asthma: sensitisation of bronchi and upper airways to dermatophyte antigen. Lancet. 1989;1(8643):859–862.
80. Pronina EV, Karaev ZO, Alferov VP. Increased sensitivity to Candida in patients with bronchial asthma. Pediatria. 1990;5:14–18.
81. Strazzella WD, Safirstein BH. Asthma due to parasitic infestation. N J Med. 1989;86(12):947–949.
82. Burney P. A diet rich in sodium may potentiate asthma. Epidemiologic evidence for a new hypothesis. Chest. 1991;91(6 suppl):143S–148S.
83. Burney PGJ, Britton JR, Chinn S, et al. Response to inhaled histamine and 24 hour sodium excretion. BMJ. 1986;292:1483–1486.
84. Burney PGJ, Neild JE, Twort CH, et al. Effect of changing dietary sodium on the airway response to histamine. Thorax. 1989;44(1):36–41.
85. Carey OJ, Locke C, Cookson JB. Effect of alterations of dietary sodium on the severity of asthma in men. Thorax. 1993;48(7):714–718.
86. Knox AJ. Salt and asthma. BMJ. 1993;307:1159–1160.
87. Mickleborough TD. Salt intake, asthma, and exercise-induced bronchoconstriction: a review. Phys Sportsmed. 2010;38(1):118–131.
88. Daviskas E, Gonda I, Anderson SD. Local airway heat and water vapour losses. Respir Physiol. 1991;84(1):115–132.
89. Fedoseev GB, Trofimov VI, Sinitsina TM, et al. [Current views on the role of disorders of hormonal regulation in the development of altered sensitivity and reactivity of the bronchi]. Vestn Akad Med Nauk SSSR. 1989;2:29–33.
90. van Aalderen WM, Meijer GG, Oosterhoff Y, Bron AO. Epidemiology and the concept of underlying mechanisms of nocturnal asthma. Respir Med. 1993;87(suppl B):S37–S39.
91. Haczku A, Panettieri RA, Jr. Social stress and asthma: the role of corticosteroid insensitivity. J Allergy Clin Immunol. 2010;125(3):550–558.
92. Di Marco F, Santus P, Centanni S. Anxiety and depression in asthma. Curr Opin Pulmon Med. 2011;17(1):39–44.
93. Scanlon TR, Chang S. Brain norepinephrine: a possible role in bronchial asthma. Ann Allergy. 1988;60(4):333–338.
94. Beynon HL, Garbett ND, Barnes PJ. Severe premenstrual exacerbations of asthma: effect of intramuscular progesterone. Lancet. 1988;2:370–372.
95. Skobeloff EM, Spivey WH, Silverman R, et al. The effect of the menstrual cycle on asthma presentations in the emergency department. Arch Intern Med. 1996;156(16):1837–1840.
96. Rumbak MJ, Kelso TM, Arheart KL, Self TH. Perception of anxiety as a contributing factor of asthma: indigent versus nonindigent. J Asthma. 1993;30(3):165–169.
97. Mrazek DA, Klinnert MD, Mrazek P, Macey T. Early asthma onset: consideration of parenting issues. J Am Acad Child Psychiatry. 1991;30(2):277–282.
98. Skloot G, Permutt S, Togias A. Airway hyperresponsiveness in asthma: a problem of limited smooth muscle relaxation with inspiration. J Clin Invest. 1995;96(5):2393–2403.
99. Dozor AJ. The role of oxidative stress in the pathogenesis and treatment of asthma. Ann N Y Acad Sci. 2010;1203:133–137.
100. Riedl MA, Nel AE. Importance of oxidative stress in the pathogenesis and treatment of asthma. Curr Opin Allergy Clin Immunol. 2008;8(1):49–56.
101. Boljevic S, Daniljak IG, Kogan AH. Changes in free radicals and possibility of their correction in patients with bronchial asthma. Vojnosanit Pregl. 1993;50(1):3–18.
102. Flatt A, Pearce N, Thomson CD, et al. Reduced selenium in asthmatic subjects in New Zealand. Thorax. 1990;45(2):95–99.
103. Kashalikar SJ. A common denominator in the pathogenesis of asthma. Med Hypotheses. 1988;27(4):255–259.
104. Dorsch W, Adam O, Weber J. Antiallergic and antiasthmatic effects of onion extracts. Folia Allergol Immunol Clin. 1983;30(suppl 4):17.
105. Braquet P. Proofs of involvement of PAF-acether in various immune disorders using BN 52021 (ginkgolide B): a powerful PAF-acether antagonist isolated from Ginkgo biloba L. Adv Prostaglandin Thromboxane Leukot Res. 1986;16:179–198.
106. Atal CK, Sharma A, Kaul A, Khajuria A. Immunomodulating agents of plant origin. I: Preliminary screening. J Ethnopharmacol. 1986;18(2):133–141.
107. Udupa AL, Udupa SL, Guruswamy MN. The possible site of anti-asthmatic action of Tylophora asthmatica on pituitary-adrenal axis in albino rats. Planta Med. 1991;57(5):409–413.
108. Bone K. Clinical Applications of Ayurvedic and Chinese Herbs. Warwick, Australia: Phytotherapy Press, 1996. pp. 134–136
109. Chang HM, But PP. Pharmacology and Applications of Chinese Materia Medica. Singapore: World Scientific, 1987.
110. Nagai H, Osuga K, Koda A. Inhibition of hypersensitivity reactions by soluble derivatives of baicalein. Jpn J Pharmacol. 1975;25:763.
111. Amella M, Bronner C, Briancon F, et al. Inhibition of mast cell histamine release by flavonoids and bioflavonoids. Planta Med. 1985;1:16–20.
112. Kubo M, Matsuda H, Tanaka M, et al. Studies on Scutellariae radix. VII. Anti-arthritic and anti-inflammatory actions of methanolic extract and flavonoid components from Scutellariae radix. Chem Pharm Bull (Tokyo). 1984;32(7):2724–2729.
113. Tanno Y, Shindoh Y, Takishima T. Modulation of human basophil growth in vitro by xiao-qing-long-tang (syo-seiryu-to), chai-pu-tang (saiboku-to), qing-fei-tang (seihai-to), baicalein and ketotifen. Am J Chin Med. 1989;17(1–2):45–50.
114. Taniguchi C, Homma M, Takano O, et al. Pharmacological effects of urinary products obtained after treatment with saiboku-to, a herbal medicine for bronchial asthma, on type IV allergic reaction. Planta Med. 2000;66(7):607–611.
115. Tripathi RM, Sen PC, Das PK. Studies on the mechanism of action of Albizzia lebbeck, an Indian indigenous drug used in the treatment of atopic allergy. J Ethnopharmacol. 1979;1(4):385–396.
116. Tripathi RM, Sen PC, Das PK. Further studies on the mechanism of the anti-anaphylactic action of Albizzia lebbeck, an Indian indigenous drug. J Ethnopharmacol. 1979;1(4):397–400.
117. Atal CK. Chemistry and Pharmacology of Vasicine: A New Oxytocic and Abortifacient. Jammu-Tawi: Regional Research Laboratory, 1980.
118. Chopra RN, et al. Chopra’s Indigenous Drugs of India, 2nd ed. Calcutta: Academic Publishers, 1982.
119. World Health Organization. The Use of Traditional Medicine in Primary Health Care: A Manual for Health Workers in South-East Asia. New Delhi: WHO Regional Office for South-East Asia, 1990.
120. Wagner H, Bladt S. Plant Drug Analysis: A Thin Layer Chromatography Atlas, 2nd ed. Berlin: Springer-Verlag, 1996.
121. Rastogi RP, et al, 1990–1994. Compendium of Indian Medicinal Plants, Lucknow and New Delhi, Central Drug Research Institute and National Institute of Science Communication, 1998;vol 5.
122. Bruce RA, Kumar V. The effect of a derivative of vasicine on bronchial mucus. Br J Clin Pract. 1968;22(7):289–292.
123. Aulakh GS, Mahadevan G. Herbal drugs for asthma – a review of clinical evaluation of anti-asthmatic drugs. Indian Drugs. 1989;26(11):593–599.
124. McLaughlin SP. Grindelia New Crop Factsheet. University of Arizona, 1995. Office of Arid Lands Studies
125. Mills S, Bone K. The Essential Guide to Herbal Safety. USA: Churchill Livingstone, 2005. pp. 457–458
126. British Herbal Medicine Association. British Herbal Pharmacopoeia. Bournemouth: BHMA, 1983.
127. Felter HW, Lloyd JU. King’s American Dispensatory, 18th ed., rev 3, vol II. First published, Portland, 1905; reprinted Sandy, Oregon, Eclectic Medical Publications, 1983.
128. Hoang BX, Shaw DG, Levine S, et al. New approach in asthma treatment using excitatory modulator. Phytother Res. 2007;21:554–557.
129. Li X-M. Traditional Chinese herbal remedies for asthma and food allergy. J Allergy Clin Immunol. 2007;120:25–31.
Urinary system
Apart from their use to provide non-specific support for recuperation and repair, specific phytotherapeutic strategies include the following.
Because of its use of secondary plant products, extreme caution is necessary in applying phytotherapy in cases of:
Plants have been used as diuretic remedies thoughout history (Pliny the Elder mentions that many plants have diuretic properties in his Naturalis Historia1). However, the early indications for such use were often different: urinary stones, nephritis, cystitis, strangury, urinary retention and incontinence.2 The excruciating pain of urinary stones would of course be well known and would have driven many urgent treatments. Because of the severity of such conditions, diuretic remedies would have been more drastic than nowadays. Remedies would have been given in much higher doses, for shorter duration, and stronger agents were used. The diuretic effects of purgatives, for example, were well understood and these may well have been used in desperate attempts to relieve the symptoms of ascites in advanced liver failure – a not uncommon condition given the frequency of hepatitis. (This reputation of laxatives, although easily experienced, remains unsupported in clinical research, although it has been found in vivo that anthraquinone derivatives induce experimental diuresis associated with the inhibition of ATPases in the kidney medulla.3) Another drastic treatment of dropsy forms the basis of one of medicine’s best historical stories. When William Withering found that the active principle of one effective remedy for dropsy was the cardioactive foxglove he initiated a whole new medical tradition as well as confirming that dropsy was a symptom of heart failure rather than of the kidneys (see also Chapter 2).
Inducing appreciable consistent diuresis generally involves drastic pharmacological activity and modern diuretic drugs are powerful agents. Examples of plants with direct diuretic effects producing consistent activity in controlled conditions in the literature are rare, and there are some studies that specifically show a negative effect in these circumstances.4–7 There is, for example, the suggestion that essential oils may prove to have direct effects on tubular function: a paper on the effects of aqueous parsley seed extract has implicated tubular inhibition of the sodium/potassium pump, albeit with relatively large doses in rats, that would lead to a reduction in sodium and potassium reabsorption and an osmotic water flow into the urinary lumen.8 Other examples where a diuretic effect has been observed experimentally include a study showing significant increase in 24-hour urine volume, urine and serum sodium levels in nine mild hypertensives administered a whole-plant preparation of Phyllanthus amarus.9 In another study, Aerua lanata flowers at doses of 10 g induced significant diuresis in 70% of subjects in uncontrolled clinical conditions.10 A study on a product based on asparagus and parsley root has also shown limited diuretic effect in the management of congestive heart failure.11 The benefits of the Indian remedy Terminalia arjuna bark extract at 500 mg every 8 hours, as adjuvant therapy to conventional medications, have been attested in a double blind, crossover trial on 12 patients with chronic congestive heart failure (although this is most likely a cardiac rather than a renal effect).12
There is some evidence of diuretic effects of various popular diuretics in experimental animals, but often at very high doses (40 mL/kg13 and 1 g/kg14,15), levels outside any therapeutic range. Other plants with experimental diuretic effects in animals that have been observed at various dosages include Taraxacum (dandelion),16 members of the Equisetum family,17 Orthosiphon leaf18 and Orthosiphon seeds,19 various Solidago species,20,21Agrimonia eupatoria (agrimony),22Lactuca virosa (wild lettuce)23 and Parietaria (pellitory).24 Diuretic activity (including renal vasodilation and urinary sodium excretion) has been observed in experimental studies on Clerodendron trichotomum,25 and Rehmannia radix.26 However, studies on Alpinia speciosa27 and Polygonum punctatum28 showed no diuretic properties in spite of other pronounced pharmacological activities, and the main effect in rats of administering oral doses of Opuntia ficus-indica infusions was a marked loss of potassium, with only modest diuresis and sodium loss at lower concentrations.29
In more recent pharmacological studies, several common herbs have exhibited interesting diuretic activity that might prove clinically relevant, including fennel (see fennel monograph). Others have been the subject of an extensive 2007 review.30 A few clinical trials have also been undertaken. Powdered cherry stalk (Cerasus avium) at 2 g caused a mild increase in urine volume in 13 healthy volunteers in an open label trial.31 In another open label, pilot study, three 8 mL doses in 1 day of a hydroethanolic extract of fresh dandelion leaf given to 17 healthy volunteers caused a significant (p<0.05) increase in the frequency of urination in the 5-hour period after the first dose.32 There was also a significant (p<0.001) increase in the excretion ratio in the 5-hour period after the second dose of extract. The third dose failed to change any of the measured parameters. The herb Eclipta alba leaf powder 3 g/day caused a remarkable increase in urine volume (34%) and urine sodium (24%) in a placebo-controlled 60-day trial involving 60 mildly hypertensive patients.33
The modest research evidence apart, the experience of even mild herbal prescriptions having sometimes dramatic diuretic effects is well known to practitioners and this is one of the most common reactions to treatment that patients report. One conclusion that can be drawn is that diuretic responses are variable, perhaps reflecting other indeterminate susceptibilities in the individual patient.
Two variations on the diuretic theme have emerged from earlier Western traditions. In German practice, the concept of ‘aquaretic’ has been used to describe diuretic agents that excrete water from the body, most probably associated with potassium, but not other electrolyte, excretion.34 They may exert their effect due to increased blood flow to the kidney. Most herbal diuretics in tradition are likely to be of this class. They are thus not easily comparable with modern diuretics that interfere with resorption at the distal tubule of the nephron, leading to wider electrolyte elimination, and thus may be less effective in treating hypertension and oedematous conditions. They are speculated to act on the glomerulus, increasing fluid loss from the body in a physiological manner by increasing the formation of primary urine.35
In the case of hypertension, the main benefit of herbal aquaretics may be in replacing the potassium lost through the use of modern diuretic prescriptions. High potassium levels relative to sodium have been shown to be a feature of herbal drugs with traditional diuretic activity.36 Compared to a ratio in the average diet of 2:1, herbal remedies such as Urtica (nettle tops), Equisetum (horsetail), Betula (birch), Sambucus (elder), Agrimonia (agrimony), Phaseolus vulgaris (bean pods), Matricaria (chamomile) and tilia (lime flowers) had ratios greater than 150:1 potassium to sodium, especially in decoction form. It is difficult with current information to link high potassium levels to any aquaretic or diuretic effect, but given that diuresis is almost by definition accompanied by potassium loss, to have an effective potassium supplement seems convenient.
The herb combination that has been most studied in the context of aquaretic activity is asparagus root (Asparagus officinalis) with parsley herb (Petroselinum crispum).11 In uncontrolled trials, this combination caused significant weight loss in overweight patients and significantly lowered blood pressure in patients with hypertension, without changing other biochemical parameters.11
In the case of oedema, phytotherapeutic strategies should emphasise activity on other body functions (see below) rather than any diuretic impact.
A second concept of ‘diuretic depurative’ is more compatible with the general meaning of diuretics in Western herbal tradition; it implies that the remedy removes metabolites and waste products as well as water, that is as an aid to excretion.
There is one very gentle diuretic mechanism that may underlie the effect of several plants.
The principle of osmotic diuresis has been established since the end of the 19th century when Ustimowitsch, Falck and Richet stressed the influence of urinary solutes on urine flow, although over a century earlier Segalas and Wohler observed that an extra load of urea, or any other substance that is excreted by the kidney, causes a diuresis.37
The osmotic plant-based diuretic mannitol is used, by intravenous injection, in acute oliguric renal failure.38 Mannitol is found in some plants, including the popular diuretic Elymus repens (couch grass); however, its absorption from the gut wall is limited and it is unlikely to play a significant role in the effect of couch grass. Nevertheless, a number of similar sugar molecules may account for a gentle diuretic effect of many herbal remedies, as well as, more generally, fruits and vegetables. For example, the plant starch inulin is used in commercial preparations to measure glomerular filtration rate and in experiments of kidney microperfusion as a marker of tubular water reabsorption. A number of plant extracts of inulin have been shown to have a comparable effect.39
Although clearly active in the elimination of water from the body and the control of fluid levels within the tissues, the impact of the kidneys in oedema is not always obvious, compared with a failing heart, a cirrhotic liver or lymphatic or venous insufficiency in their relevant syndromes. Nevertheless, in all such cases prescription of conventional diuretic drugs is commonplace and it is widely assumed that the kidney is centrally involved in most cases.
This assumption has mixed support in the scientific literature. For example, renal complications of liver cirrhosis are certainly implicated in the development of ascites. These complications include inadequate renal prostaglandin production and the negative effect on the kidney of raised nitric oxide production. Such complications may actually reduce the effect of diuretics, but they remain indicated in the treatment of ascites as long as they are effective.40 In phytotherapy, however, the main effort now would be on using hepatics and other treatments for the liver.
Although undoubtedly effective symptomatically, the value of diuretics used alone for congestive heart failure in the long term has been challenged, because of their possible excitation of the renin-angiotensin system. Concomitant prescription of ACE inhibitors has been proposed and positively evaluated, because they suppress this excitation.41 As seen below, herbal diuretics are unlikely to raise the same concerns but may be only second-tier treatments compared to the cardioactive glycosides.
The localised oedema of lymphatic and venous insufficiency is treated in phytotherapy with particular remedies said to act on the vessel walls. These may have incidental diuretic effects.
In phytotherapy, there are few traditional strategies that are likely to bear directly on the kidney cortex itself, with emphasis placed instead on activity lower down the urinary system. Nevertheless, little is known about the full impact of plant constituents on this organ and, although there are very few cases where actual nephrotoxicity occurs, a general caution in using herbal treatments is advisable where the kidneys are already damaged.42
Kidney disease such as glomerulonephritis and cystic disease presents awesome and possibly overwhelming odds for the phytotherapist. By definition the kidney in such cases, especially where the basement membrane is involved, is vulnerable to further damage with any new active metabolite and the practitioner needs to proceed with extreme caution. Nevertheless, there is experimental and case report evidence, mainly from China and Japan, suggesting that some herbal remedies might have beneficial effects in such cases, including such conditions as nephrotic syndrome (Chinese herbs Astragalus and Angelica (see monographs),43 diabetic nephropathy (Abemoschus manihot44) and other kidney diseases.45–49Andrographis paniculata has shown experimental ability to reduce pyuria and haematuria as complications of urinary stone destruction (see Andrographis monograph)50 and magnesium lithospermate B, a component of Lycopus and Lithospermum species, has shown potential as a therapeutic agent for inhibiting the progression of renal dysfunction.51 The use of various Chinese bitter (‘cooling and drying’) herbs has been shown to improve biochemical markers associated with free radical damage in patients with chronic glomerulonephritis compared with matched controls.52
Other plant materials have shown apparent antinephrotoxic activity and may provide the basis for strategies following the adverse effects of heavy metals, antibiotics, analgesic and other prescription drugs, Amanita mushroom and aflatoxins and industrial agents. Protective effects of Arctostaphlos uva-ursi, Orthosiphon stamineus and Polygonum aviculare have been noted against the nephrotoxic effects of mercuric chloride,53 and beneficial effects against the nephrotoxin aminoglycoside in elderly patients have also been noted in controlled studies for Cordyceps sinensis.54 Aqueous rhubarb extract (at 150 mg/day) reduced proteinurea and glomerulosclerosis in rats exposed to experimental chronic renal fibrosis in controlled models.55 More recently curcumin and Withania have demonstrated nephroprotective activity in vivo (see monographs) and there have been some interesting reviews of this topic.56–59
As noted above, most plants used primarily for their effects on the urinary system are collectively referred to as ‘diuretics’ in many texts. Nevertheless, this covers a broad range of traditional activities and probably very variable actual diuretic effects so the terms ‘aquaretics’ and ‘diuretic depuratives’ (see above) may be more accurate. However, the conventional terminology will be used here, as demarcation between the two categories is currently inadequate.
• Dysuria and oliguria linked to urinary infections or stones (although simply increasing fluid intake can achieve the same flushing effect)
• Heart failure (as an adjunct to cardioactive glycosides)
• Ascites (combined with hepatic remedies)
• Nocturnal enuresis and other functional disturbances of micturition
The use of diuretic herbs may be inappropriate and possibly even contraindicated in the following:
The traditional treatment of arthritic disease often involved using herbs that were otherwise considered diuretics. There is a more modern tradition that suggests these diuretics act to increase the elimination of metabolic acid wastes (e.g. uric acid), factors popularly associated with arthritic disease. The precise explanation for the apparent efficacy of remedies such as birch, celery seed and nettle leaf in arthritic diseases may be more complex.
This tradition is a reminder of the wider assumption that diuretics were among the eliminative strategies applied to a range of toxic conditions associated especially with inflammatory diseases and persistent or recurrent infections (see p. 149). Any hint of fluid retention accompanying such conditions would be a traditional indication for diuretics.
Diuretics, when prescribed overtly as such, are best taken in relatively high quantities at any time relative to eating. However, dramatic diuresis in some cases may follow quite small doses of many herbs, perhaps directed to other ends.
Phased treatments may be appropriate, for example, early morning and lunchtime dosages as part of a strategy for treating nocturnal enuresis.
• Arctostaphylos uva-ursi (bearberry, see monograph), Vaccinium macrocarpon (cranberry), Barosma betulina (buchu, see monograph), Juniperus communis (juniper), Berberis vulgaris (barberry, see monograph), Chimaphila umbellata (pipsissewa), Hydrastis canadensis (golden seal), Piper cubeba (cubeb).
The main role of cranberry appears to be in the prevention of urinary tract infections; possibly by reducing bacterial adherence to the bladder wall.60 The accumulated evidence for its role in this regard is relatively good, especially in terms of managing recurrent infections.61,62
These agents will exert a soothing effect on the lining of the urinary tract and are indicated for inflammation and infections such as urethritis and cystitis. They may also be of value for inflammation higher up the urinary tract and the irritation of kidney stones. Some urinary tract demulcents such as marshmallow leaf act by a reflex effect (reflex demulcents). Others, specifically couch grass and corn silk probably have a direct effect.
These herbs decrease the likelihood of urinary stone formation and may also act to weaken and slowly dissolve existing stones. Antilithic herbs include Crataeva, horsetail, gravel root (Eupatorium purpureum), parsley piert (Aphanes arvensis) and pellitory of the wall (Parietaria species). Gravel root may act particularly against uric acid stones, whereas the other herbs act on mineral stones. Some antilithics such as Crataeva63 can help the expulsion of small stones.
These herbs have a toning effect on the smooth muscle of the bladder. They are therefore useful in the treatment of hypotonic bladder, as can occur with the urinary outlet obstruction caused by benign prostatic hyperplasia, and other neurological conditions of the bladder. During bladder infection, bacteria may remain with the residual urine that is left in the bladder after each voiding. Bladder tonics decrease this residual volume and therefore assist greatly with the flushing of the bladder. In this context they can be particularly valuable in the resolution of recurrent cystitis. The best established bladder tonic is Crataeva bark.63
In Western herbal terminology kidney tonics are herbs which tonify the function of the kidneys and may be useful in poor kidney function in conjunction with diuretic depuratives. They may also help protect the kidney during diseases such as glomerulonephritis. Unfortunately there is little reliable information about herbs that might have this role. In the European tradition, Solidago virgaurea (golden rod) stands out64 and there could also be a role for horsetail in this context.
In traditional Chinese medicine the term ‘kidney tonic’ is also used, but it has no relationship with the anatomical kidney. The ‘kidney tonics’ of Chinese medicine are typically adrenal cortex tonics. It is important that they are not confused with the above.
A theme that emerges from the research is the complexity of mineral and electrolyte disturbance, involving other body systems, which can underlie urinary stone formation. For example, the pathogenesis of renal calculi may involve relative changes in concentrations of other urinary trace elements, notably copper and phosphorus,65 that clearly reflect wider metabolic changes.
In industrialised countries, about 80% of stones that form in the kidneys are composed of calcium salts and usually occur as calcium oxalate and less commonly calcium phosphate.66,67 The remaining 20% of stones are largely composed of uric acid, struvite or cystine.
Because urine is supersaturated with calcium, crystal formation occurs readily if urine calcium rises, as when there is fluid depletion or increased calcium excretion. Calcium is also less soluble as the urine becomes more alkaline. Factors in urine that inhibit crystallisation processes include:68
• magnesium, which complexes oxalate
• citrate, which complexes calcium
• pyrophosphate, which impairs crystallisation of calcium oxalate.
About 50% of patients with calcium stones have excessive calcium in their urine. The most common cause of this is a genetically determined increased calcium absorption in the intestine. Excessive urinary calcium can also be caused by a diet rich in sodium or animal protein. Low levels of citrate in the urine is another factor, which affects between 20% and 60% of patients.66 Factors involved here can include urinary tract infection, a high sodium intake, chronic diarrhoea, potassium loss, excessive physical exercise and an excessively acid-forming diet (rich in high protein foods). High excretion of oxalate in the urine is largely of dietary or genetic origin. Ironically, the dietary factor most often responsible for oxalate stones is a low calcium intake. However, reducing the intake of oxalates is probably a safer option than increasing dietary calcium beyond normal levels,68 although calcium supplementation has been shown to be beneficial in stone prevention.69
High protein consumption may be a factor in stone formation, since the resultant sulphates formed generate an acid load in the urine that is buffered by bone.67 Animal protein also has a high purine content, which will increase uric acid excretion. An inverse relationship occurs between renal potassium and calcium excretion, which brings attention to the role of potassium-rich fruits and vegetables as preventatives.67 Obesity and insulin resistance are linked to both calcium and uric acid stones.67,70
Recurrent oxalate stone formers are significantly less likely to be colonised with the gut-dwelling bacterium Oxalobacter formigenes.71 This organism is able to degrade dietary oxalate. Probiotic use of lactic acid bacteria that metabolise oxalate might also provide a valid alternative to this organism.
Lifestyle and diet are best aimed at preventing stone formation, and, since the recurrence rate of stones is 75% over 20 years, the following guidelines could be followed by all patients with a history of kidney stones.66
Regular weight-bearing exercise will help store calcium in bones, which would otherwise be excreted in the urine. However, exercise should not be excessive since this increases dehydration and can cause lactic acidosis, both factors in stone formation. Fluid intake should be adequate, especially in warm climates, but commercial drinks are to be avoided (these are sometimes loaded with phosphate and sugar).
The diet should be based on fruit, vegetables and unrefined carbohydrates. Animal protein (including cheese) intake should not be excessive and dietary salt should be restricted.72 Fruit, which is rich in potassium and citrate, should be emphasised, together with foods rich in magnesium such as fermented soya products, legumes, nuts and green leafy vegetables. Calcium intake, specifically dairy foods, should be moderate, but should also not be restricted unless there are other reasons for this, such as dairy protein allergy. Restriction of calcium can lead to excessive oxalate absorption.73 If there is a history of oxalate stones, then foods rich in oxalate are best avoided. These include rhubarb, spinach, strawberries, ginger, almonds, cashews and beetroot. A probiotic supplement may be relevant here as well.
There is substantial evidence of interaction between urinary urates and oxalates, so that higher urinary levels of the former, following disturbances of purine metabolism including gout, can lead to ‘salting out’ of calcium oxalate stones; drugs such as allopurinol, which reduce urinary urate, also reduce oxalate stones.74 This calls into question the use, in the case of incipient or actual oxalate calculi (for example, in cases of severe small intestinal disease as above), of some plants such as the fruits of Apium graveolens (celery) and Petroselinum crispum (parsley), Eupatorium purpureum (gravel root), Betula spp. (birch) and Urtica dioica (nettle leaf), that are considered to increase urinary excretion of urates.
Other studies suggest that urate stones themselves may be linked to low blood urate levels following enhanced tubular secretion of urate within the kidney. In such cases, agents increasing urate excretion would be clearly contraindicated and alkalinisation of urine may be the most effective treatment,75 since overly acidic urine is the key feature of these types of stones. It may be the factor that connects the disorder with metabolic syndrome.76,77
In pregnancy, hyperuricuria and hypercalciuria, changes in metabolic inhibitors of lithiasis formation, urinary stasis, relative dehydration and the presence of infection all increase the likelihood of stone formation.78
In seven plants (Verbena officinalis, Lithospermum officinale, Taraxacum officinale, Equisetum arvense, Arctostaphylos uva-ursi, Arctium lappa and Silene saxifraga) studied for their effects on experimental risk factors for urinary stones (citraturia, calciuria, phosphaturia, pH and diuresis), moderate solvent action on uric stones was linked to the alkalinising capacity of the herb infusion and to a possible urinary antiseptic activity.79
Other Asiatic herbal products have been shown to reduce experimental renal stone formation.80–82 In Ayurveda, Crataeva nurvala is highly acclaimed for its use in the management of urinary tract disorders, especially kidney stones. Research has demonstrated a range of activity on urinary structures, including improved performance in clinical studies of benign prostatic hyperplasia83 and with urinary stones84,85 and in reducing oxalate stone formation,86 with the steroid lupeol being a possible active constituent.87 A pharmacological study found that Crataeva influenced small intestinal Na,K-ATPase, which in turn influenced the transport of minerals.88 This is a reminder that oxalate problems may well originate from the digestive tract (see above).
Herbal teas in general have been recommended as alternatives to the usual black tea consumption because of the latter’s association with increased risk of formation of calcium oxalate stones, but this is unlikely to reflect a general benefit of plant extractives as such.89
Herbal treatment can augment the above dietary and lifestyle measures designed to prevent kidney stones and can also be used to treat existing stones. The regime is largely the same for these two treatment scenarios. In the case of managing existing stones, therapy is aimed at passing small stones and/or gradually weakening or dissolving larger stones:
• A key herb is Crataeva, which research has shown can assist the passage of small stones and prevent the formation of new stones (see the detailed information above). Other antilithic herbs such as horsetail and golden rod are indicated, as are aquaretics which will render the urine more dilute (as will copious fluid intake). Dandelion leaf is also useful, given that it is rich in potassium.
• Anthraquinone-containing herbs such as cascara and yellow dock can help by binding calcium in the urine and making it less likely to precipitate. The herb madder (Rubia tinctorum) was particularly used for this effect in Europe, but has now been banned due to concerns over carcinogenicity.
• Infection can provide a focus for stone formation; hence the treatment strategies for cystitis should also be followed if infection is thought to play a role. This includes immune supporting herbs such as Echinacea root and antibacterial herbs such as cranberry and buchu. However, there is some clinical evidence to suggest that cranberry may slightly increase the risk of oxalate stone formation.90
• If a stone is lodged and causing pain then urinary tract demulcents and spasmolytic herbs such as cramp bark and wild yam are additionally indicated. The prescription-only spasmolytic Ammi visnaga was traditionally used in Egypt to aid the passage of urinary stones. While stones are causing damage to the urinary tract mucosa, immune-enhancing herbs and urinary tract antiseptics will lower the risk of infection. A species of oak Quercus salicina (Q. stenophylla) has been used to treat urinary stones in Japan since 1969. Clinical trials have demonstrated efficacy in assisting the passage of both renal and ureteral stones.91,92
Urinary infections are very common, affecting for example up to 20% of women at some time in their lives. Practitioner experience is that herbal remedies can be effective treatments for conditions such as urethritis, cystitis, ureteritis and even pyelonephritis (especially if chronic). Infections of the prostate gland (i.e. prostatitis) are also potentially amenable, although two general caveats are raised here. There are usually legal and ethical issues in the way of tackling urinary infections of venereal origin without referral to conventional sexually transmitted disease clinics. From a clinical point of view also, a urinary infection that has progressed beyond the walls of the tubules, as in pyelitis and prostatitis, can present other treatment challenges. That being said, the judicious use of the urinary antiseptics described below is often productive and there are many cases of recurrent cystitis that have been permanently corrected with phytotherapy.
Several plant constituents have at least theoretical antiseptic effects when eliminated in the urinary tract and a number of plants have firm clinical reputations for long-term efficacy in uncomplicated urethritis and cystitis, especially when caused by Gram-negative bacteria such as Escherichia coli (accounting for 80% of adult cases), Staphyloccocus saprophyticus, Klebsiella and Proteus.
When urinary tract infections are complicated by pregnancy, diabetes, immunosuppression or other abnormalities, prudence will determine that these are considered before simple urinary antiseptics are applied. Except in pregnancy and severe kidney disease, however, the treatments are rarely contraindicated. They may also show effectiveness in urinary tract conditions linked to fungal (e.g. Candida) and parasitic infections (for example, following malaria, leishmaniasis, trichomoniasis and bilharziasis) and for those without obvious infective cause. In the last case at least alkalinisation of the urine is a helpful accompaniment, conventionally with half a teaspoon of sodium bicarbonate in water every 3 to 4 hours but also with increased consumption of fruit juice (and vegetable juice especially).
Urinary infection probably requires adhesion of the bacteria to the otherwise glassy surface of the urinary tract and those usually responsible have mechanisms to do this. Constituents of berries of the heather family, notably Vaccinium macrocarpon (cranberry) and V. myrtillus (blueberry, bilberry), appear at least in vitro to interfere with this adhesion mechanism,93 especially in the case of Escherichia coli (responsible for 80% of such infections). This may be due to the D-mannose in the berries preferentially adhering to the bacterial surface, or to proanthocyanins. There have been a number of clinical trials pursuing this effect and recently an updated Cochrane report chose 10 that were of methodologically good quality for systematic review and four for meta-analysis. The conclusion from the latter was that cranberry juice products can be effective in reducing urinary tract infections, although perhaps favouring women and having less impact in the elderly.62 They pointed to more work being needed, particularly in establishing effective dosage and other elements of treatment regime.
The benefits of cranberry may be pointers to the clinical benefits seen with its relative, Arctostaphylos uva-ursi (bearberry), although in this case it is the leaves that are used and it is the conversion of the glycoside arbutin into the antiseptic hydroquinone in the urinary tract that is seen as the likely mechanism.94 Another traditional urinary antiseptic Chimaphila umbellata (pipsissewa) also contains arbutin.95 (Also see the bearberry monograph.)
Another plant constituent with clinical antiadhesive properties, at least in the gut and in synthetic form, is berberine from the Berberis genus including Berberis aquifolium (Oregon grape) and Hydrastis canadensis (golden seal), both used traditionally for cystitis.96 These also have separate activity against E. coli, Klebsiella spp. and other urinary pathogens (see berberis monograph).
It is also possible that herbs may help in the condition known as interstitial cystitis. This difficult condition, marked by inflammatory infiltration in the bladder wall but no obvious infection, is generally thought to be an autoimmune disorder. However, an infective cause has not been ruled out,97 and in spite of its name, it appears that there is no increased bladder permeability.98 There do appear to be changes in neurotransmitter sensitivity (increasing resistance to atropine and histamine and a switch towards purinergic transmission in parasympathetic nerve terminals)99 and impairment of bladder perfusion in patients has also been observed, especially when the bladder was full.100 It is for these reasons that in herbal treatments urinary antiseptics can be combined with other agents with an apparent benefit on the bladder wall (e.g. Equisetum, Zea, Crataeva nurvula and Althaea).
A major and debilitating problem is recurrent acute bacterial cystitis (otherwise known as recurrent cystitis), where the woman suffers repeated acute infections, often close to one another. As already noted the bacteria that cause cystitis can cling to and invade the cells lining the bladder wall and there they can remain dormant and resistant to antibiotic attack. Their activation leads to the next infection. Up to 20% of young women with cystitis develop recurrent infections of the urinary tract.101
Recurrent cystitis responds positively to herbal treatment, which is recommended on a continuing basis to prevent the acute attacks. After freedom from acute infections for 3 to 4 months, the herbal treatment can be reduced and eventually discontinued if the response is still favourable. Dietary measures (especially cranberry intake) should then continue, including reduced refined carbohydrate intake and dairy products. Adequate fluid intake should be ensured. Also, during acute cystitis any use of herbs needs to be combined with copious intake of fluid to flush the bladder. Cystitis is an infection, so it is always a good idea to support the immune system. For this either Echinacea root or the Ayurvedic herb Andrographis paniculata can be used. In a clinical trial Andrographis prevented the typical development of urinary tract infections in patients undergoing shock wave therapy for kidney stones (see andrographis monograph). Andrographis is appropriate at around 6 g/day during acute cystitis and about 3 g/day of Echinacea root can be used to prevent recurrent cystitis.
Other herbs to consider in cystitis include urinary tract demulcents such as couch grass and corn silk and licorice (Glycyrrhiza glabra), which may reduce bacterial adherence to the bladder wall (see licorice monograph).
Echinacea purpurea/angustifolia root | 1:2 | 35 mL |
Barosma betulina | 1:2 | 20 mL |
Glycyrrhiza glabra (high in glycyrrhizin) | 1:1 | 15 mL |
Zea mays | 1:1 | 30 mL |
total | 100 mL |
Dose: 8 mL with water 3–4 times daily.
Case history
A 26-year-old woman presented with recurrent bouts of cystitis. She had been experiencing these attacks for about 7 years, but they had increased in frequency since she became sexually active. In the past 18 months the frequency of her cystitis had been particularly high, and she had tried many courses of antibiotics, some very powerful. Her cystitis symptoms were almost continuous by her first herbal consultation, but in frustration she had ceased all antibiotics about 6 weeks prior.
Results of all investigations were normal and a procedure during which the trigone area of the bladder had been scraped had failed to change the frequency or morbidity of her cystitis.
The patient was advised to drink 100 mL/day cranberry juice and prescribed the following formulation:
Echinacea angustifolia/purpurea root | 1:2 | 50 mL |
Barosma betulina | 1:2 | 30 mL |
Glycyrrhiza glabra | 1:1 | 25 mL |
Crataeva nurvala | 1:2 | 45 mL |
total | 150 mL |
Dose: 8 mL with water three times daily.
After 5 weeks of herbal treatment the patient reported no cystitis, only two mornings of mild burning which passed without developing further. Following another 6 weeks of treatment, the report was the same. Her dose was then adjusted to 8 mL twice a day without adverse consequences.
The rationale for the herbal treatment was as follows (see also above):
• Echinacea improves immunity and thereby decreases the tendency to infections.
• Buchu is a urinary tract antiseptic.
• Licorice contains compounds that decrease bacterial adherence to the bladder wall.
• Crataeva improves bladder tone and reduces residual volume in the bladder, which decreases residual bacteria in the bladder.
Childhood sleep (nocturnal) enuresis (bedwetting) is the inappropriate voiding of urine by a child who has reached the age at which satisfactory control is expected. Since a large proportion of young children wet their beds, it is inappropriate to use the term enuresis until at least 5 years of age. At least 90% of children with nocturnal enuresis are reliably dry during the day.102
More than 80% of children with nocturnal enuresis have never been dry at night for a prolonged period, but nearly all will have had an occasional dry night. This can be referred to as intermittent enuresis. True primary enuresis, in which the child has never had a single dry night, is very rare. Secondary (or acquired) enuresis is less prevalent than intermittent enuresis, and is where enuresis develops after the age of 5 years in a child who has previously been reliably dry at night for at least 1 year.102
Nocturnal enuresis is more common in boys, first-born children, lower social classes and in children who have experienced stress in early life.102 Given the association with families, genetic factors may be involved with this disorder. Disorders such as diabetes, renal failure, urological abnormalities and epilepsy are rarely the cause, but should be excluded.
Stress is probably a factor, especially in relapses. Obviously the condition itself can be stressful. A child with nocturnal enuresis may have a smaller functional bladder capacity (that is, the child has the habit of emptying the bladder when it contains a relatively small volume of urine).103 Urinary tract infection is not common, but should be tested for. Constipation can be an unrecognised factor and should be attended to.104 Food allergies may be present (especially dairy, wheat or yeast) and soft drinks, tea and coffee should be avoided. Sleep apnoea should be considered and appropriate measures taken if relevant (including herbal treatment for adenoids and sinus conditions).
It is now generally agreed that nocturnal polyuria, detrusor overactivity and high arousal thresholds are, in various combinations, central to enuresis pathogenesis.105
In addition to the measures described above, the following considerations can be useful. If the child shows symptoms consistent with food allergies or intolerances, then a relevant exclusion diet should be tested. Intake of refined carbohydrates should be reduced and a natural whole food diet followed as much as possible.
Restriction of fluid intake is not helpful. In fact increasing fluid intake during the day to generate higher urine flow rates increases the awareness of bladder filling and, by encouraging urine holding, achieves an increase in functional bladder size.106
Many research projects have confirmed the merits of conditioning using alarms. Body-worn alarms are usually preferred.106,107 Rewarding dry nights can reinforce behaviour. It might be particularly valuable to reward dry nights without making an obvious connection, so that a subconscious impression is encouraged.
Key herbs to consider are as follows:
• The bladder-toning effect of Crataeva is helpful, particularly in conjunction with increased diurnal fluid intake. Horsetail has been traditionally prescribed for nocturnal enuresis and may have a similar function to Crataeva.
• St John’s wort is another traditional treatment and its nervine tonic and mild antidepressant activities will alleviate the vicious cycle of stress. Other nervine tonics such as skullcap can be considered.
• Chamomile is another nervous system herb that is particularly relevant for children. Stronger calming herbs such as valerian should not be excluded if the need arises.
• Urinary tract demulcents such as corn silk will alleviate any irritation of the urinary tract; ribwort is traditionally used.
• Allergies may need to be treated with herbs such as Albizia and Baical skullcap.
The following formula is an example treatment for an 8-year-old child:
Hypericum perforatum | 1:2 | 25 mL |
Crataeva nurvala | 1:2 | 35 mL |
Zea mays | 1:1 | 20 mL |
Equisetum arvense | 1:2 | 20 mL |
100 mL |
Dose: 4 mL with water twice a day (morning and afternoon).
Case history
A mother came with her 8-year-old son seeking treatment for his nocturnal enuresis. He had always had the problem. While his enuresis improved during school holidays, on average he was only dry for a maximum of two to three consecutive nights. During the school term he would wet the bed almost every night. He was a highly strung boy, suffered nightmares, was easily agitated, prone to respiratory allergies and a very fussy eater. He found school stressful and difficult.
The following formulation was prescribed:
Hypericum perforatum | 1:2 | 20 mL |
Zizyphus spinosa | 1:2 | 20 mL |
Passiflora incarnata | 1:2 | 15 mL |
Crataeva nurvala | 1:2 | 30 mL |
Plantago lanceolata | 1:2 | 25 mL |
total | 110 mL |
Dose: 5 mL with water twice a day.
For the first 2 weeks he experienced dry nights, the first time ever in his life. However, this was followed by wetting every night for the next 2 weeks. Over the ensuing 6 months of treatment there was a gradual improvement, to the point that wetting the bed was a rare event. The mixture was reduced to one dose a day. Over the ensuing 2 years the bedwetting would return from time to time when he was stressed, but reinstitution of the mixture at the full dose quickly restored the dry nights.
References
1. Melillo L. Diuretic plants in the paintings of Pompeii. Am J Nephrol. 1994;14(4–6):423–425.
2. Aliotta G, Capasso G, Pollio A, et al. Joseph Jacob Plenck (1735–1807). Am J Nephrol. 1994;14(4–6):377–382.
3. Zhou XM, Chen QH. Biochemical study of Chinese rhubarb. XXII. Inhibitory effect of anthraquinone derivatives on Na+-K+-ATPase of the rabbit renal medulla and their diuretic action. Yao Hsueh Hsueh Pao. 1988;23(1):17–20.
4. Doan DD, Nguyen NH, Doan HK, et al. Studies on the individual and combined diuretic effects of four Vietnamese traditional herbal remedies (Zea mays, Imperata cylindrica, Plantago major and Orthosiphon stamineus). J Ethnopharmacol. 1992;36(3):225–231.
5. Goonaratna C, Thabrew I, Wijewardena K. Does Aerua lanata have diuretic properties? Indian J Physiol Pharmacol. 1993;37(2):135–137.
6. Black HR, Ming S, Poll DS, et al. A comparison of the treatment of hypertension with Chinese herbal and Western medication. J Clin Hypertens. 1986;2(4):371–378.
7. Laranja SM, Bergamaschi CM, Schor N. Evaluation of three plants with potential diuretic effect. Rev Assoc Med Bras. 1992;38(1):13–16.
8. Kreydiyyeh SI, Usta J. Diuretic effect and mechanism of action of parsley. J Ethnopharmacol. 2002;79(3):353–357.
9. Srividya N, Periwal S. Diuretic, hypotensive and hypoglycaemic effect of Phyllanthus amarus. Indian J Exp Biol. 1995;33(11):861–864.
10. Udupihille M, Jiffry MT. Diuretic effect of Aerua lanata with water, normal saline and coriander as controls. Indian J Physiol Pharmacol. 1986;30(1):91–97.
11. Von Beitz G, Hippe SK, Schremmer D. Asparagus-P, das pflanzliche Diuretikum in der Herz-Kreislauf-Therapie. Naturheilpraxis. 1996;2:247–252.
12. Bharani A, Ganguly A, Bhargava KD. Salutary effect of Terminalia arjuna in patients with severe refractory heart failure. Int J Cardiol. 1995;49(3):191–199.
13. De Ribeiro RA, De Barros F, De Melo MM, et al. Acute diuretic effects in conscious rats produced by some medicinal plants used in the state of Sao Paulo, Brasil. J Ethnopharmacol. 1988;24(1):19–29.
14. Cáceres A, Girón LM, Martínez AM. Diuretic activity of plants used for the treatment of urinary ailments in Guatemala. J Ethnopharmacol. 1987;19(3):233–245.
15. Cáceres A, Saravia A, Rizzo S, et al. Pharmacologic properties of Moringa oleifera. 2: Screening for antispasmodic, antiinflammatory and diuretic activity. J Ethnopharmacol. 1992;36(3):233–237.
16. Racz-Kotilla E, Racz G, Solomon A. The action of Taraxacum officinale extracts on the body weight and diuresis of laboratory animals. Planta Med. 1974;26:212–217.
17. Pérez Gutiérrez RM, Laguna GY, Walkowski A. Diuretic activity of Mexican equisetum. J Ethnopharmacol. 1985;14(2–3):269–272.
18. Englert J, Harnischfeger G. Diuretic action of aqueous Orthosiphon extract in rats. Planta Med. 1992;58(3):237–238.
19. Casadebaig-Lafon J, Jacob M, Cassanas G, et al. Adsorbed plant extracts, use of extracts of dried seeds of Orthosiphon stamineus benth. Pharm Acta Helv. 1989;64(8):220–224.
20. Leuschner J. Anti-inflammatory, spasmolytic and diuretic effects of a commercially available Solidago gigantea herb extract. Arzneimittelforschung. 1995;45(2):165–168.
21. Chodera A, Dabrowska K, Sloderbach A, et al. Effect of flavonoid fractions of Solidago virgaurea L on diuresis and levels of electrolytes. Acta Pol Pharm. 1991;48(5–6):35–37.
22. Giachetti D, Taddei E, Taddei I. Diuretic and uricosuric activity of Agrimonia eupatoria L. Boll Soc Ital Biol Sper. 1986;62(6):705–711.
23. Gu WZ, Deng LJ. Studies on the chemical constituents of the essential oil in the seed of Lactuca setiva L. and its diuretic action. Chung Yao Tung Pao. 1987;11(33–35):63.
24. Giachetti D, Taddei E, Taddei I. Diuretic and uricosuric activity of Parietaria judaica L. Boll Soc Ital Biol Sper. 1986;62(2):197–202.
25. Lu GW, Miura K, Yukimura T, Yamamoto K. Effects of extract from Clerodendron trichotomum on blood pressure and renal function in rats and dogs. J Ethnopharmacol. 1994;42(2):77–82.
26. Lee HS, Kim ST, Cho DK. Effects of rehmanniae radix water extract on renal function and renin secretion rate in unanesthetized rabbits. Am J Chin Med. 1993;21(2):179–186.
27. Mendonca VL, Oliveira CL, Craveiro AA, et al. Pharmacological and toxicological evaluation of Alpinia speciosa. Mem Inst Oswaldo Cruz. 1991;86(suppl 2):93–97.
28. Simões CM, Ribeiro-do-Vale RM, Poli A, et al. The pharmacologic action of extracts of Polygonum punctatum Elliot (= P. acre HBK). J Pharm Belg. 1989;44(4):275–284.
29. Perfumi M, Tacconi R. Effect of Opuntia ficus-indica flower infusion on urinary and electrolyte excretion in rats. Fitoterapia. 1996;67(5):459–464.
30. Wright CI, Van-Buren L, Kroner CI, Koning MM. Herbal medicines as diuretics: a review of the scientific evidence. J Ethnopharmacol. 2007;114(1):1–31.
31. Hooman N, Mojab F, Nickavar B, Pouryousefi-Kermani P. Diuretic effect of powdered Cerasus avium (cherry) tails on healthy volunteers. Pak J Pharm Sci. 2009;22(4):381–383.
32. Clare BA, Conroy RS, Spelman K. The diuretic effect in human subjects of an extract of Taraxacum officinale folium over a single day. J Altern Complement Med. 2009;15(8):929–934.
33. Rangineni V, Sharada D, Saxena S. Diuretic, hypotensive, and hypocholesterolemic effects of Eclipta alba in mild hypertensive subjects: a pilot study. J Med Food. 2007;10(1):143–148.
34. Schilcher H, Emmrich D. Pflanzliche Urologika zur Durchspülungstherapie. Deutsche Apotheker Zeitung 1992;132(47):2549–2555. In: Awang DVD (ed). Tyler’s Herbs of Choice: The Therapeutic Use of Phytochemicals. 3rd ed, USA: CRC Press; 2009, p. 59.
35. Werk W. Wasser ausleiten: elektrolytneutral. Erfahrungsheilkunde. 1994;11:712–714.
36. Szentmihályi K, Kéry A, Then M, et al. Potassium-sodium ratio for the characterisation of medicinal plant extracts with diuretic activity. Phytother Res. 1998;12:163–166.
37. Richet GC. Osmotic diuresis before Homer W. Smith: a winding path to renal physiology. Kidney Int. 1994;45(4):1241–1252.
38. Archer DP, Freymond D, Ravussin P. Use of mannitol in neuroanesthesia and neurointensive care. Ann Fr Anesth Reanim. 1995;14(1):77–82.
39. Dias-Tagliacozzo GM, Dietrich SMC, Mello-Aires M. Measurement of glomerular filtration rate using inulin prepared from Vernonia herbacea, a Brazilian native species. Braz J Med Biol Res. 1996;29(10):1393–1396.
40. Roberts LR, Kamath PS. Ascites and hepatorenal syndrome: pathophysiology and management. Mayo Clinic Proc. 1996;71(9):874–881.
41. Taylor SH. Refocus on diuretics in the treatment of heart failure. Eur Heart J. 1995;16(suppl):7–15.
42. Markell MS. Herbal therapies and the patient with kidney disease. Q Rev Nat Med. 1997;Fall:189–200.
43. Li L, Wang H, Zhu S. Hepatic albumin’s mRNA in nephrotic syndrome rats treated with Chinese herbs. Chung Hua I Hsueh Tsa Chih. 1995;75(5):276–279.
44. Yu JY, Xiong NN, Guo HF. Clinical observation on diabetic nephropathy treated with alcohol of Abelmoschus manihot. Chung Kuo Chung Hsi I Chieh Ho Tsa Chih. 1995;15(5):263–265.
45. Li P, Fujio S. Effects of chai ling tang on proteinuria in rat models. J Tradit Chin Med. 1995;15(1):48–52.
46. Zheng JF, Chen SY. Observations on therapeutic effects of huangdan decoction and Tripterygium wilfordii compound tablet on membranous glomerulonephritis in rats. J Tongji Med Univ. 1995;15(1):31–34.
47. Shida K, Imamura K, Katayama T, et al. Clinical efficacy of sairei-to in various urinary tract diseases centering on fibrosis. Hinyokika Kiyo. 1994;40(11):1049–1057.
48. Kawachi H, Takashima N, Orikasa M, et al. Effect of traditional Chinese medicine (sairei-to) on monoclonal antibody-induced proteinuria in rats. Pathol Int. 1994;44(5):339–344.
49. Ren G, Chang F, Lu S, et al. Pharmacological studies of Polygonum capitatum Buch Ham. ex D. Don. Chung Kuo Chung Yao Tsa Chih. 1995;20(2):107–109. 128
50. Muangman V, Viseshsindh V, Ratana-Olarn K, Buadilok S. The usage of Andrographis paniculata following extracorporeal shock wave lithotripsy (ESWL). J Med Assoc Thai. 1995;78(6):310–313.
51. Yokozawa T, Zhou JJ, Hattori M, et al. Effects of a Dan Shen component, magnesium lithospermate B, in nephrectomized rats. Nippon Jinzo Gakkai Shi. 1995;37(2):105–111.
52. Yu EK. Anti-free radical damage of chronic glomerulonephritis with febrifugal and diuretic medicinal herbs. Chung Kuo Chung Hsi I Chieh Ho Tsa Chih. 1993;13(8):464–466. 452
53. Shantanova LN, Mondodoev AG, Lonshakova KS, Nikolaev SM. Pharmacotherapeutic effectivity of plant nephrophyte polyextractions in cases of mercuric chloride necronephrosis. Rastitel’nye Resursy. 1996;32(1–2):110–117.
54. Bao ZD, Wu ZG, Zheng F. Amelioration of aminoglycoside nephrotoxicity by Cordyceps sinensis in old patients. Chung Kuo Chung Hsi I Chieh Ho Tsa Chih. 1994;14(5):271–273. 259
55. Zhang G, El Nahas AM. The effect of rhubarb extract on experimental renal fibrosis. Nephrol Dial Transplant. 1996;11(1):186–190.
56. Wojcikowski K, Johnson DW, Gobé G. Medicinal herbal extracts – renal friend or foe? Part two: herbal extracts with potential renal benefits. Nephrology (Carlton). 2004;9(6):400–405.
57. Wojcikowski K, Johnson DW, Gobe G. Herbs or natural substances as complementary therapies for chronic kidney disease: ideas for future studies. J Lab Clin Med. 2006;147(4):160–166.
58. Li X, Wang H. Chinese herbal medicine in the treatment of chronic kidney disease. Adv Chronic Kidney Dis. 2005;12(3):276–281.
59. Jha V. Herbal medicines and chronic kidney disease. Nephrology (Carlton). 2010;15(suppl 2):10–17.
60. Côté J, Caillet S, Doyon G, et al. Bioactive compounds in cranberries and their biological properties. Crit Rev Food Sci Nutr. 2010;50(7):666–679.
61. Rossi R, Porta S, Canovi B. Overview on cranberry and urinary tract infections in females. J Clin Gastroenterol. 2010;44(suppl 1):S61–S62.
62. Jepson RG, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev;. (1):2008. CD001321
63. Bone K. Clinical Applications of Ayurvedic and Chinese Herbs. Warwick: Phytotherapy Press, 1996. pp. 112–114
64. Melzig MF. Goldenrod – a classical exponent in the urological phytotherapy. Wien Med Wochenschr. 2004;154(21–22):523–527.
65. Rodgers AL, Barbour LJ, Pougnet BM, et al. Re-evaluation of the ‘week-end effect’ data: possible role of urinary copper and phosphorus in the pathogenesis of renal calculi. J Trace Elem Med Biol. 1995;9(3):150–155.
66. Pak CYC. Kidney stones. Lancet. 1998;351:1797–1801.
67. López M, Hoppe B. History, epidemiology and regional diversities of urolithiasis. Pediatr Nephrol. 2010;25(1):49–59.
68. Whitfield HN, Mallick NP. Renal calculi. Medicine. 1995:199–204.
69. Goldfarb DS. Prospects for dietary therapy of recurrent nephrolithiasis. Adv Chronic Kidney Dis. 2009;16(1):21–29.
70. Sakhaee K, Maalouf NM. Metabolic syndrome and uric acid nephrolithiasis. Semin Nephrol. 2008;28(2):174–180.
71. Siva S, Barrack ER, Reddy GP, et al. A critical analysis of the role of gut Oxalobacter formigenes in oxalate stone disease. BJU Int. 2009;103(1):18–21.
72. Burtis WJ, Gay L, Insogna KL, et al. Dietary hypercalciuria in patients with calcium oxalate kidney stones. Am J Clin Nutr. 1994;60:424–429.
73. Curhan GC, Willet WC, Rim EB, Stampfer MJ. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med. 1993;328:833–838.
74. Grover PK, Ryall RL. Urate and calcium oxalate stones: from repute to rhetoric to reality. Miner Electrolyte Metab. 1994;20(6):361–370.
75. Hisatome I, Tanaka Y, Kotake H, et al. Renal hypouricemia due to enhanced tubular secretion of urate associated with urolithiasis: successful treatment of urolithiasis by alkalization of urine K+, Na(+)-citrate. Nephron. 1993;65(4):578–582.
76. Maalouf NM. Metabolic syndrome and the genesis of uric acid stones. J Ren Nutr. 2011;21(1):128–131.
77. Cicerello E, Merlo F, Maccatrozzo L. Urinary alkalization for the treatment of uric acid nephrolithiasis. Arch Ital Urol Androl. 2010;82(3):145–148.
78. Swanson SK, Heilman RL, Eversman WG. Urinary tract stones in pregnancy. Surg Clin North Am. 1995;75(1):123–142.
79. Grases F, Melero G, Costa-Bauza A, et al. Urolithiasis and phytotherapy. Int Urol Nephrol. 1994;26(5):507–511.
80. Yamaguchi S, Jihong L, Utsunomiya M, et al. The effect of takusha and kagosou on calcium oxalate renal stones in rats. Hinyokika Kiyo. 1995;41(6):427–431.
81. Hirayama H, Wang Z, Nishi K, et al. Effect of Desmodium styracifolium-triterpenoid on calcium oxalate renal stones. Br J Urol. 1993;71(2):143–147.
82. Kawamura K, Moriyama M, Nakajima C, et al. The inhibitory effects of Takusha on the formation, growth and aggregation of calcium oxalate crystals in vitro. Hinyokika Kiyo. 1993;39(8):695–700.
83. Deshpande PJ, Sahu M, Kumar P. Crataeva nurvala Hook and Forst (Varuna) – the Ayurvedic drug of choice in urinary disorders. Indian J Med Res. 1982;76(suppl):46–53.
84. Prabhakar YS, Kumar DS. The Varuna tree, Crataeva nurvala, a promising plant in the treatment of urinary stones. A review. Fitoterapia. 1990;61(2):99–111.
85. Varalakshmi P, Shamila Y, Latha E. Effect of Crataeva nurvala in experimental urolithiasis. J Ethnopharmacol. 1990;28(3):313–321.
86. Anand R, Patnaik GK, Kulshreshtha DK, et al. Antiurolithiatic activity of Crataeva nurvala ethanolic extract on rats. Fitoterapia. 1993;64(4):345–350.
87. Anand R, Patnaik GK, Kulshreshtha DK, et al. Antiurolithiatic and diuretic activity of lupeol, the active constituent isolated from Crataeva nurvala (Buch. Ham). Proceedings of the 24th Indian Pharmacological Society Conference, Ahmedabad, Gujarat, India, A10, 1991.
88. Varalakshmi P, Latha E, Shamila Y, et al. Effect of Crataeva nurvala on the biochemistry of the small intestinal tract of normal and stone-forming rats. J Ethnopharmacol. 1991;31(1):67–73.
89. McKay DW, Seviour JP, Comerford A, et al. Herbal tea: an alternative to regular tea for those who form calcium oxalate stones. J Am Diet Assoc. 1995;95(3):360–361.
90. Gettman MT, Ogan K, Brinkley LJ, et al. Effect of cranberry juice consumption on urinary stone risk factors. J Urol. 2005;174(2):590–594.
91. Higashi Y, Yamada H, Kobori G, et al. Clinical equivalence trial of UROCALUN miniaturized tablet in patients with upper urinary tract stone disease. Hinyokika Kiyo. 2005;51(3):215–223.
92. Watanabe K, Yuri K. [A clinical study on spontaneous passage of ureteral stone – effect of urocalun and jumping exercise to ureteral stone]. Hinyokika Kiyo. 1989;35(5):769–773.
93. Ofek I, Goldhar J, Zafiri D, et al. Anti-Escherischia adhesin activity of cranberry and blueberry juice. N Engl J Med. 1991;324:1559.
94. Schindler G, Patzak U, Brinkhaus B, et al. Urinary excretion and metabolism of arbutin after oral administration of Arctostaphylos uvae ursi extract as film-coated tablets and aqueous solution in healthy humans. J Clin Pharmacol. 2002;42(8):920–927.
95. Galván IJ, Mir-Rashed N, Jessulat M, et al. Antifungal and antioxidant activities of the phytomedicine pipsissewa, Chimaphila umbellata. Phytochemistry. 2008;69(3):738–746.
96. Rabbani GH, Butler T, Knight J, et al. Randomised controlled trial of berberine sulfate therapy for diarrhea due to enterotoxigenic Escherichia coli and Vibrio cholerae. J Infect Dis. 1987;155:979–984.
97. Warren JW. Interstitial cystitis as an infectious disease. Urol Clin North Am. 1994;21(1):31–39.
98. Ruggieri MR, Chelsky MJ, Rosen SI, et al. Current findings and future research avenues in the study of interstitial cystitis. Urol Clin North Am. 1994;21(1):163–176.
99. Paella S, Artibani W, Ostardo E, et al. Evidence for purinergic neurotransmission in human urinary bladder affected by interstitial cystitis. J Urol. 1993;150(6):2007–2012.
100. Irwin P, Galloway NT. Impaired bladder perfusion in interstitial cystitis: a study of blood supply using laser Doppler flowmetry. J Urol. 1993;149(4):890–892.
101. Williams DH, Schaeffer AJ. Current concepts in urinary tract infections. Minerva Urol Nefrol. 2004;56:15–31.
102. Meadow R. Childhood enuresis. Medicine. 1995:211–214.
103. Yeung CK. Nocturnal enuresis (bedwetting). Curr Opin Urol. 2003;13(4):337–343.
104. Robson WL. Current management of nocturnal enuresis. Curr Opin Urol. 2008;18(4):425–430.
105. Nevéus T. Diagnosis and management of nocturnal enuresis. Curr Opin Pediatr. 2009;21(2):199–202.
106. Knapp M. How to treat enuresis. Australian Doctor1994;(August suppl): i–vii.
107. Mathew JL. Evidence-based management of nocturnal enuresis: an overview of systematic reviews. Indian Pediatr. 2010;47(9):777–780.
Nervous system
Apart from their use to provide non-specific support for recuperation and repair, specific phytotherapeutic strategies include the following.
Treatment in some circumstances of:
As with any pharmacological agent, particular caution is necessary in applying phytotherapy in cases of:
Although herbal remedies are not exactly comparable to conventional drugs in terms of directness of action, it is most likely that the primary effect of plant constituents on the nervous system is similar in terms of the synaptic junctions between nerve and nerve and nerve and muscle or other tissue. The receptor sites involved, whether on the presynaptic or postsynaptic membranes, are the communication junctions in the nervous system where its modulation is generally effected. The transmitter chemicals involved are among the most powerful molecules in the body and play a major part in the functions of other body systems; as seen in the relevant chapters of this book, plant constituents have been widely shown to engage with receptors in the hormonal, immunological and other control systems in the body. These systems form a whole, whose study, psychoneuroimmunology, has attracted the attention of the more imaginative medical researchers since the 1960s. The ability of plant constituents to engage cell receptors is also a particular feature of activity within the digestive system, which in clinical reality for herbal remedies is probably the most accessible interface in the chemical control of the nervous system.
There are ample opportunities for herbal constituents to interact with synaptic function in the nervous system. Various herbal extracts have been shown in vitro to act on adrenergic and cholinergic,1 muscarinic, 5-HT1A and 5-HT2 receptors, dopamine (D1 and D2), the benzodiazepine and the gamma-aminobutyric acid (GABA) binding sites.2,3 Notable examples of such activity follow; the literature cited reflects the fact that much published research in this area emanates from China and Japan. While these experimental examples might not always reflect real clinical effects, some are given here to reflect the wide spectrum of possible activities of herbal remedies.
A modification of the movement of calcium ions through channels in the cell wall is a common factor in many receptor mechanisms. As well as the calcium channel-blocking effect of opioid alkaloids like protopine and tetrandine4 (and see the Analgesic section below), this has also been observed in vascular tissues for ginseng saponins.5,6 A coumarin, scoparone, from Capillaris also inhibits calcium influx.7 From the Chinese remedy Dictamnus dasycarpus, calcium channel block was found with fraxinellone and dictamine, two constituents with vasorelaxant effect.8
The adrenergic effects of alkaloids of Ephedra, ephedrine and pseudoephedrine, have been understood for many years. Beta-2-adrenergic receptor stimulation has also been mooted to explain the effect of Angelica sinensis in reducing experimental pulmonary hypertension.9 The nociceptive effect of processed aconite was demonstrated as involving adrenergic rather than opioid receptors10 and hypaconitine appears to be the most active of the alkaloids.11 The bronchorelaxant (antiasthmatic) effect of coumarins in the fruit of Cnidium monnieri is mediated by a beta-2 receptor and blocked by propranolol.12
Plant remedies with anticholinergic effects (i.e. blocking acetylcholine receptors) are important in traditional medicine. Acetylcholine-sensitive or ‘cholinergic’ receptors are divided into many types, depending on their other sensitivities. ‘Nicotinic’ receptors are also sensitive to the alkaloid from Nicotiana tabacum (tobacco). ‘Muscarinic’ receptors are also sensitive to muscarine from the fly agaric mushroom. The atropine-like alkaloids in plants of the Solanaceae (such as deadly nightshade, henbane and jimson weed) block muscarinic receptors in the parasympathetic nervous system. As well as these well-known alkaloidal cholinergic blockers, there are likely to be other plants with more modest, though significant, positive effects on these receptors. For example, the effect of dried orange peel on digestive activity was blocked by atropine, suggesting activity on the muscarinic receptors.13 More modern interest in this category has focused on a potential role of herbal products in the management of Alzheimer’s disease.14
The benzodiazepine drug valium was named in recognition of recent research that had established valerian as manifesting some tranquillising properties. Although there are no chemical similarities between valerian constituents and benzodiazepines, some pharmacological similarities have emerged, with evidence that, like the benzodiazepines, valerian acts in part through an effect on the receptors on inhibitory neurons sensitive to GABA (see also the valerian monograph). GABA-A and benzodiazepine receptor binding has been shown as a feature of a number of herbal remedies.15,16 For example, Salvia miltiorrhiza (dan shen), much researched in Beijing as a postulated treatment for ischaemic damage after strokes,17 and in the repair of other nerve tissue damage,18 has effects which apparently include stimulating GABA release19,20 and blocking calcium input.21
The main pharmacological interest in dopaminergic activity is in Parkinsonism research and a number of plants have shown some promise in pharmacological research, though not yet clinically.22 The Ayurvedic herb Mucuna pruriens is a natural source of L-DOPA also showing promise in the management of Parkinson’s disease.23 Tetrahydrocolumbamine from Polygala tenuifolia inhibits dopamine receptors, in part competitively,24 as does tetrahydropalmatine from Corydalis (and see below). (In the monograph on chaste tree other evidence for dopaminergic receptor activity is outlined.)
Analgesics present a major challenge to the modern phytotherapist. Painkillers are by definition relatively powerful agents. Natural analgesics are likely to have been identified early in human history for their immediate benefits in pain relief and/or for their psychoactive properties. Obvious examples are the opium poppy (morphine alkaloids), the nightshade family (atropine alkaloids), willow (see monograph), poplar and birch barks among other sources of salicylates and phenols, as well as the many psychoactive plants (coca, cannabis, psilocybin, mescaline, etc.). Most are now only legally prescribed by doctors, if at all, and it would appear that there is little scope for relatively gentle remedies to compete with the improved targeting of synthetic analgesics.
There are, however, a number of traditional remedies with general and specific analgesic reputations that have been less well exploited in modern times and which are relatively well tolerated in clinical use. Although not as powerful as some of the modern synthetic analgesics, they do show sufficient activity to be taken seriously and are particularly likely to be helpful in pain linked to inflammation and to visceral and vascular spasm. The research papers cited in the following examples demonstrate that even in the demanding area of analgesia there is ample evidence to support useful clinical intervention by the phytotherapist. None of the following remedies are safe for widespread use by the public; their use is to be confined to the experienced clinician who can take account of all factors, including the increased likelihood of adverse effects.
A traditional medicinal plant of the Indians, this herb is now used mainly by the rural population of western USA for its mild analgesic and sedative properties (and as the state flower of California). In studies on a prescription herbal formulation in Germany containing E. californica and Corydalis cava (see below) at 4:1 relative concentration, investigators identified interactions with opioid receptors,25 as well as other neurotransmitter activity.26 Aqueous alcoholic extracts from E. californica also were shown to inhibit the enzymatic degradation of catecholamines as well as the synthesis of adrenaline, dopamine beta-hydroxylase and monoamine oxidase (MAO-B).27 A clinical trial of a mixture of Eschscholtzia, Crataegus (hawthorn) and magnesium showed significant benefits compared with placebo in reducing the symptoms of anxiety.28
A key alkaloidal constituent, chelerythrine, is a well-known protein kinase C inhibitor with antitumour activity (see also the Chelidonium monograph).29 Activation of protein kinase C in spinal cord dorsal horn neurons contributes to persistent pain following noxious thermal30 and chemical stimulation; chelerythrine produced significant reductions of nociceptive responses in one study.31 Another Canadian study suggests that chelerythrine can attenuate the development of morphine dependence.32 It also demonstrates a range of potent anti-inflammatory activities.33,34
Chelerythrine and another alkaloidal constituent, sanguinarine, exhibited affinity for rat liver vasopressin V1 receptors and are competitive inhibitors of [3H]-vasopressin binding. These alkaloids represent two of the first non-peptidic structures providing original chemical leads for the design of synthetic vasopressin compounds.35
This remedy has been widely used in China and the East for pain, especially of dysmenorrhoea and the abdomen. In the studies referred to above on its combination with E. californica, Corydalis cava was generally the stronger of the two ingredients.
Whole Corydalis extract demonstrated antispasmodic activity in acetylcholine-induced contractions at around half that seen for papaverine,36 and its isoquinoline constituents including familiar alkaloids such as protopine, berberine and palmatine have exhibited anticholinesterase activity.37 Consistently with the pharmacological profiles of this group, isocoryne produced an inhibitory effect on GABA-activated currents.38 Isocorypalmine has close affinity for the D1 dopamine receptor.39 Dehydrocorydaline appears to block noradrenaline release and an experimental antiulcerative action is posited.40 Corydalis also has powerful anti-inflammatory effects.41,42
Traditional vinegar-processed preparations of the fresh Corydalis tuber have been shown to have stronger analgesic effects in vivo than those of the dried preparation.43 There appeared to be higher concentrations of total alkaloids in the fresh specimen.44
This remedy was traditionally used for pain, especially arising from abdominal and digestive causes with headaches and abdominal pain, including dysmenorrhoea.
At least some of the effectiveness of Evodia has been linked to the fraction containing evodiamine and rutaecarpine.45 A cholinergic mechanism has been implicated in this activity.46,47 On the other hand, in the case of Evodia’s vasodilatory activity, an alpha-adrenoceptor blocking and 5-HT antagonising action are suggested,48 including for a recent isolate, synephrine,49 as well as for the powerful cardiotonic and uterotonic evodiamine50,51 and for the vasorelaxant and hypotensive dehydroevodiamine.52,53 Direct action on muscarinic receptors has been linked to its antidiarrhoeal action.54
Among a number of plants tested, Evodia showed a strong inhibitory effect on acetylcholinesterase in vitro55 and an antiscopolamine effect in vivo. This antiamnesic effect was more potent than that of tacrine, an older drug for Alzheimer’s disease approved by the FDA.56 The active component was identified as dehydroevodiamine hydrochloride.
Modern research is investigating a number of medicinal plants for anxiolytic activity. The key anxiolytic herbs covered by monographs in this text are Piper methysticum (kava) and Valeriana officinalis (valerian). Withania (Withania somnifera), hawthorn (Crataegus species) and Ginkgo (Ginkgo biloba) have also demonstrated clinical anxiolytic effects, and these trials have been included in their respective monographs.
Another anxiolytic herb with a growing body of evidence is passionflower (Passiflora incarnata). The unusual common name is not a reference to earthly passions. It comes instead from the Christian symbolism (Christ’s Passion) seen in the flower by the Spanish conquistadores when they first encountered the vine growing in South America. This was later elaborated by the scholarly monk Jacomo Bosio, who maintained that the flowers contained a profound symbolism of Christ’s final days on earth.57 For example, the five stamens were the number of wounds, the three pistil stigmas represented nails and the 72 filaments were the number of thorns in the crown given to Jesus.
Despite this focus on the flower, the part of the plant used medicinally is the aerial part or the vine. Phytochemicals found here that contribute to the anxiolytic activity are not fully understood, but they include flavonoids, maltol and flavonoid-related molecules such as benzoflavone.58
There are now several clinical trials providing evidence to support the value of passionflower for anxiety symptoms. In a pilot, randomised, double blind, controlled trial, passionflower extract was as efficacious as oxazepam for the management of generalised anxiety disorder. However, herbal treatment resulted in a lower incidence of impairment of job performance. The daily dosage of the undefined passionflower extract was 45 drops.59 A passionflower and valerian combination improved symptoms of insomnia in uncontrolled trials.60,61 The side effects characteristic of benzodiazepine tranquilisers were not observed.61 In a controlled trial with comparison against chlorpromazine (an antipsychotic drug), electroencephalographic (EEG) recordings showed a sedative activity after 6 weeks’ treatment with the herbal combination.60 In a randomised, double blind, placebo-controlled study, a single dose of passionflower extract (equivalent to about 7 g of dried herb) demonstrated a calming effect in healthy female volunteers, as assessed by a self-rating scale for alertness.62
Passionflower has also been used to help drug withdrawal symptoms. A randomised, double blind, controlled, 14-day trial compared clonidine plus passionflower extract against clonidine plus placebo in the outpatient detoxification of opiate addicts. Both treatments were equally effective at treating the physical symptoms of withdrawal, but the group receiving passionflower showed superiority over clonidine alone in terms of the management of mental symptoms.63
Many patients suffer from anxiety before surgery, but any premedication must be sufficiently strong without causing undue sedation or interacting with general anaesthesia. A recent clinical study found that a single dose of passionflower prior to outpatient surgery reduced anxiety without increasing sedation.64 In a double blind, randomised, placebo-controlled trial, 60 patients received either 500 mg of passionflower herb as a tablet or a matching placebo as a premedication 90 minutes before surgery. The passion flower tablet was standardised to contain 1.01 mg of benzoflavone. A numerical rating scale of 1 to 10, with 10 being the worst possible anxiety, was used to assess anxiety and sedation before and 10, 30, 60 and 90 minutes after premedication. Psychomotor function was assessed at arrival in the operating theatre and 30 and 90 minutes after tracheal extubation. Anxiety scores were similar for both groups at baseline, being 4.6±1.7 for the passionflower group and 5.1±2.0 for the placebo control group. After 90 minutes these had changed to 0.97 for the herbal treatment versus 3.88 for control treatment (p<0.001). There were no significant differences between the groups in the level of sedation before surgery and the recovery of function after surgery. Discharge times were also similar and no side effects were observed.
A clinical study presented as a poster at the European College of Neuropsychopharmacology Congress held in Vienna during October 2007 found that a combination of St John’s wort (Hypericum perforatum) and passionflower was helpful for the symptoms of depression with anxiety.65 Each tablet in the combination contained 450 mg of St John’s wort extract (about 2.7 g of herb) and 350 mg of passionflower extract (about 1.4 g of herb) and it was given at a dose of 2 per day. In the trial, 162 patients received either the herbal tablets or a matching placebo for 8 weeks using a randomised, double blind design. Herbal treatment resulted in a highly significant reduction in the Hamilton depression score in the mildly depressed patients (15.64±0.93 to 8.05±1.69) versus an increase for placebo. Results were similar for anxiety scores, indicating that the anxiety that often accompanies mild depression also responded to the herbal combination, no doubt due largely to the passionflower.
Preliminary findings from a clinical trial suggest passionflower improves subjective sleep quality, a result entirely consistent with its traditional reputation as a mild hypnotic. A double blind, placebo-controlled trial conducted in Australia investigated the efficacy of passionflower on sleep.66 Forty-one healthy volunteers (18 to 35 years) without extreme sleep problems received passionflower or placebo for 1 week, then after a 1-week washout they received the other treatment for 1 week. They drank a cup of tea 1 hour before bedtime. The tea was prepared from 2 g passionflower or placebo (parsley, Petroselinum crispum; 2 g) in 250 mL of boiling water, infused for 10 minutes. There was a significant improvement in sleep quality when taking passionflower (5.2% mean increase relative to placebo; p<0.01). No significant effects were found for other parameters, although the participants had initially low levels of anxiety.
Herbs with antidepressant activity form part of the herbal category known as the nervine tonics (or nervous system trophorestoratives). The best known example is St John’s wort (Hypericum perforatum), which is the subject of a lengthy monograph in this book.
In addition, there is some encouraging research that has highlighted some unlikely herbal candidates for antidepressant activity, namely lavender (Lavandula officinalis) and saffron (Crocus sativa). Also, perhaps not unexpectedly, the tonic herb Rhodiola now has some reasonable evidence for a supporting role in depression.
Lavender has a strong reputation as a herb for the nervous system. In aromatherapy it has been used to calm anxiety and boost mood for some time. The use of lavender oil in depression is also supported by evidence from clinical studies.67 A small double blind clinical trial was conducted to compare the oral use of 60 drops/day of a lavender 1:5 tincture with the drug imipramine.68 A third group of patients also took both treatments. While the lavender tincture showed some benefit, it was not as effective as the imipramine for depression. Perhaps a higher dose of lavender might have yielded better results, as the dose used in the trial was quite low. But the interesting finding was that the combination of lavender with imipramine worked better than imipramine alone, without any accentuation of the drug’s side effects.
The evidence for saffron is more extensive, with a number of clinical trials showing promising results, although again these are all small, involving around 40 patients each. Trials tested its efficacy against a placebo and against conventional antidepressants, both a tricyclic (imipramine) and a selective serotonin re-uptake inhibitor (fluoxetine).
Two double blind placebo-controlled trials found that saffron extract at a dose of just 30 mg/day was significantly better (p<0.001) than placebo in improving the mood of patients with mild to moderate depression.69,70 There were no more side effects in the saffron group than in the placebo. There was a dramatic drop in the Hamilton depression rating scale for the patients taking the saffron that was evident at 2 weeks and continued to fall until the end of the trial at 6 weeks. In all, it fell from around 23 to 9 in the group taking saffron, versus a fall of only around 23 to 18 in the placebo group.
In the comparative clinical trials, saffron was found to be as effective as the conventional drugs tested. In the trial comparing saffron with imipramine, patients taking the drug experienced the typical side effects of a dry mouth and excessive sedation.71 No such side effects occurred for saffron. Saffron was compared with fluoxetine in two published trials72,73 and found to have a similar remission rate for depression to the drug, of around 25%. There were no significant differences between the two patient groups in terms of side effects.
Saffron is a very expensive spice and dye commonly used in Indian and Middle Eastern cuisine. The reason why it is expensive is that just a small part (the stigma) of each flower of this attractive Crocus is harvested by hand.
Research from Sweden has supported the role of Rhodiola rosea in depression.74 In an experimental model of depression Rhodiola performed as well as St John’s wort and the antidepressant drug imipramine. The activity was dose dependent and several key phytochemicals in Rhodiola including rosavin were shown to be active.
This research led to a clinical trial of Rhodiola extract in mild and moderate depression. In a randomised, double blind, placebo-controlled design, male and female patients aged 18 to 70 years with Hamilton Rating Scale for Depression (HAMD) scores of 21 to 31 were divided into three groups.75 Over 6 weeks Group A (31 patients) received 340 mg/day of Rhodiola extract, Group B (29 patients) received 680 mg/day of extract and Group C (29 patients) were assigned a matching placebo. Both the Hamilton and the Beck Depression Inventory (BDI) were used to assess treatment outcomes at 6 weeks. The BDI is a series of questions developed to measure the intensity, severity and depth of depression.
In terms of overall depression, there were highly significant reductions (p<0.0001) in both the HAMD and BDI scores 6 weeks after Rhodiola treatment that was not evident in the placebo group. The average HAMD score in Groups A and B fell from around 25 to around 18 for both groups, indicating that a dose-response effect was not seen for this outcome. In contrast, a dose-response relationship was observed for the BDI scale, with values falling from around 11 to 8 in Group A and from about 11 to 5 in Group B. In terms of the HAMD subgroup scores, significant reductions were seen for insomnia, emotional instability and somatisation (physical symptoms caused by mental or emotional factors), but not for self-esteem (except in the high dose Group B). No serious side effects were seen.
In discussing a mechanism of action for Rhodiola, the authors emphasised its adaptogenic and antistress activities.74 In depression it is theorised that stress hormones such as cortisol and indeed the HPA (hypothalamic-pituitary-adrenal) axis are overactivated and do not switch off appropriately via the normal negative feedback (see later in this section). The influence of certain stress chemicals released by cells (stress kinases) is thought to play a key role in this overactivity. In particular, they inhibit the sensitivity of receptors in the brain to cortisol. In an experimental model, Rhodiola extract decreased the release of stress kinases and cortisone in response to stress. This suggests that Rhodiola inhibits the stress-induced activation of stress kinases in depressed patients and so restores the impaired sensitivity of their brain receptors to cortisol. This ‘resistance’ of the cortisol receptors is a noted feature in many patients with major depression (see also p. 338).
• Corydalis spp. (yan hu suo), Eschscholtzia californica (California poppy), Evodia rutaecarpa (wu zhu yu), Gelsemium sempervirens (yellow jasmine), Paederia scandens (ji shi teng), Piscidia erythrina (Jamaica dogwood). Topically: Bryonia alba (white bryony), Piper methysticum (kava), Syzygium aromaticum (clove bud).
As powerful agents, herbal analgesics should be restricted in their application to experienced and well-trained practitioners only. There is a theoretically increased risk of neurotoxicity and other adverse effects (although little known incidence) and there is always the possibility that individual examples could be withdrawn from use by regulatory authorities; this is most likely after cases of irresponsible use. The following cases should be approached with particular caution:
In conventional pharmacological terms, sedatives reduce nervous activity and hypnotics promote sleep. There is obviously overlap in practice between the two categories, and both imply a degree of depression of nervous activity and consequent dangers (as seen most obviously in the barbiturates). There is a third category of calming agent that was postulated as an ideal anxiolytic strategy: the tranquilliser. This was originally defined as a treatment whose effect was confined to the reticular activating system that determined the level of arousal in the central nervous system (CNS), and did not otherwise sedate. Although the benzodiazepines were hailed as tranquillisers on their discovery, this ideal has been clearly compromised and these remedies are now seen to have appreciable sedative and hypnotic effects as well.
Many traditional herbal remedies have various degrees of sedative and tranquillising activity, and some have had this effect supported in experimental and clinical studies. However, it is probably misleading to apply the strict pharmacological definitions to them; their effects are much broader in clinical experience, with strong sedation rare. For the purposes of this text, therefore, the terms ‘herbal sedatives and hypnotics’ will be used to describe remedies that are actually relaxing, with little evidence of depressive activity.
As generally milder than prescribed sedatives, herbal equivalents should not be seen as immediate substitutes in the more serious indications. It would be unwise and even dangerous to drop the use of strong sedative medication without careful planning, preferably with the cooperation of the prescribing physician:
In what were usually harsher and more robust times, the need for sedatives was often urgent, and opium extracts were the most favoured. The main tradition of use of moderate herbal sedatives was as short-term components of convalescent management, particularly to help with sleep. There was apparently little use of sedatives for wider lifestyle management.
Most medical preoccupation has been with the nervous system as an entity in itself, with the goal of better analgesics, sedatives, tranquillisers and antipsychotics. Traditional interest in such areas was of course also strong and many plants were favoured for their powerful psychoactive properties. However, probably the most widespread use of neuroactive plants, or nervines, nowadays is for their effects on innervated structures rather than on nervous tissue alone.
The spasmolytic is a modern descriptor of the effect of an agent on visceral muscle in vitro, often the isolated guinea pig ileum. The technique is widely used as a model to indicate muscarinic or related receptor activity as above, but is a property with little therapeutic application. By contrast, herbal spasmolytics or relaxants are remedies used to reduce the symptoms of tension in the body. Pre-Cartesian insights into the human condition had no separation between body and mind and this particular holistic view is a constant feature of Asian medicine still. Apart from the obvious psychoactives, remedies were not seen to be acting on the nervous system as such; rather there were many remedies that treated various manifestations of turbulence in the body linked to what nowadays would be described as ‘stress-related’ conditions.
Even though using other terms, early texts described such conditions as classic hypertension (‘Liver qi rising’), nervous headaches, palpitations, breathless attacks and hyperventilation (‘constriction of the chest’), nervous dyspepsia, dysphagia, irritable bowel and urinary frequency.
The remedies selected for these conditions were seen as somatic in emphasis. The markers for application and effectiveness were physical symptoms. Nowadays modern phytotherapists refer to many of them as antispasmodics or spasmolytics or, more recently, ‘visceral relaxants’. They are offered to the modern stressed patient as a welcome antidote to the culture of tranquillisers and sedatives, treatments working from the ‘neck down’ to reduce the physical effects of tension without befuddling the brain or impugning their sanity. Western remedies such as those listed later have all developed reputations as useful management measures in helping patients handle and even overcome psychosomatic disorders, perhaps combined with appropriate breathing exercises and adrenaline-reducing aerobic activity. Some Chinese remedies such as Uncaria rhynchophylla were targeted at such conditions and hold out the promise of modern applications.
• Corydalis spp., Dioscorea spp. (wild yam), Leonurus cardiaca (motherwort), Lobelia inflata (lobelia), Matricaria recutita (chamomile), Melissa officinalis (lemon balm), Passiflora incarnata (passionflower), Piper methysticum (kava), Scutellaria lateriflora (skullcap), Tilia spp. (lime flowers), Valeriana officinalis (valerian), Viburnum opulus (cramp bark).
As a group these remedies are generally safe and well tolerated.
Early use of spasmolytics also appears to have been dominated by their emergency indications, notably urinary and biliary colic. The use of milder relaxant treatments was mainly as tisanes for children and in the largely unrecorded but vast realm of family care. As expected, systematic classifications of medicine throughout history are generally silent on this area of popular healthcare.
Relaxants were obviously indicated for functional overactivities; indications such as dyspeptic and colicky conditions were probably the most common (and carminatives such as the spices the most frequent tisanes). Headaches, teething and restlessness in children and menstrual pains were likely to make up most of the remaining indications. These were usually treated within the home by local remedies with recipes handed down through the family.
Some remedies are more sedative than others in this class (see above). These might be added to a relaxant prescription to increase its impact. However, sedation may be depleting: the more a remedy is chosen for its sedative effects, the shorter the treatment should be and the more tonifying remedies should be added (see following section). The latter should also be a major element in prescriptions for the increasing proportion of tension conditions linked with fatigue, debility, depression and exhaustion.
Spasmolytics and relaxants (and also those aromatics and volatile spasmolytics used for this purpose) may be best taken as hot infusions, though the ordinary teabag may not be sufficiently strong compared with the traditional brew, and in acute cases traditional doses were very high indeed. However, the following herbs probably work better in aqueous ethanolic extracts: Dioscorea spp., Lobelia inflata, Passiflora incarnata, Piper methysticum, Valeriana officinalis, and Viburnum opulus.
Long-term therapy is generally well tolerated and may be appropriate, although the use of more sedative remedies should be reduced.
Herbal medicine has had to adapt significantly from its traditional roots. There is evidence that in many earlier cultures there were different perspectives on anxiety and depression syndromes. Whether there was genuinely less opportunity for the modern diagnosis in highly structured communities living on the edge of survival or whether such symptoms were not recognised as such is arguable. There is, however, less emphasis on treatments to relieve stress and mood conditions in most traditional texts.
There were also no powerful synthetic agents that relieved pain and distress. It is thus an entirely modern notion that herbs could provide gentle back-up for sufferers with nervous or mental problems.
In the West, where such adjustments have been made over many decades, the group of remedies that has emerged to meet modern needs is sometimes referred to as ‘nervines’. In recognition of the common observation that many conditions of tension are linked with fatigue, debility and depression, there is also a category of remedies that were seen to restore energies and build up strength. These have sometimes been referred to as ‘trophorestoratives’. It was a general principle that some tonifying element be included in most nervine prescriptions, so as to aim for lasting value rather than just short-term alleviation.
True trophorestoratives are almost nutritional in their effects, with few risks of adverse effects except in those patients with extremely debilitated constitutions (see also the discussion on tonics).
Neurasthenia encompassed a wider range of disorders than nervous exhaustion. In days before psychoanalysis and neurology, it included symptoms where the nervous tissues were seen to be affected such as neuralgia and neuritis, depression, anxiety states and neurosis. The trophorestoratives were thus often combined with other tonics and convalescent foods such as molasses, yeast and malt extract (now known as rich sources of the B vitamins), oatmeal and other cereals.
There are several types of anxiety defined in the various diagnostic manuals including panic disorder, phobias, social anxiety disorder, obsessive-compulsive disorder, separation anxiety and post-traumatic stress disorder. However, the condition classified as generalised anxiety disorder (GAD) is probably the most common form suffered by patients seeking phytotherapy. This is with good reason, since this often milder form of anxiety is more amenable to subtle treatments.
The DSM-IV (American Psychiatric Association 2000) defines GAD as troublesome excessive anxiety and worry (apprehensive expectation) occurring more days than not for at least 6 months and not associated with any other condition.78 Three or more of the following will be present: restlessness or feeling on edge, being easily fatigued, difficulty in concentration, irritability, muscle tension and sleep disturbances.
One interesting discussion suggests that several factors have led contemporary psychiatry away from neuroses and anxiety disorders and towards depression as a social paradigm of distress.79 These included a perception that anxiety disorders have less relevance, the downfall of the benzodiazepines and the failure to replace them with better anxiolytics, and the development of newer antidepressants. The article suggests that having promoted cognitive-behavioural therapy as the treatment for anxiety disorders, these conditions have become more the domain of clinical psychologists.
The discussion does touch on an important consideration: that patients suffering from anxiety must be viewed as a whole. Aspects of lifestyle and diet should be considered and extremes corrected where possible, for example excessive use of alcohol, recreational drugs or sexual indulgence, imbalanced diet, excessive tea and coffee intake, and cigarette smoking. Such corrections will need to be carefully considered, since often these factors can be used by the patient to allay anxiety and their abrupt withdrawal could exacerbate symptoms. Appropriate professional guidance and counselling, with the introduction of simple techniques for relaxation, can be beneficial.
Aspects of herbal treatment to be considered for the patient with GAD are as follows:
• Dampening symptoms of anxiety with anxiolytic and sedative herbs such as kava, valerian and passionflower. Other herbs in these categories can provide valuable assistance and include lavender, California poppy, Zizyphus seed, Corydalis, Magnolia and Bacopa
• The nervine tonic herbs also have a role (these herbs are calming, but also lift mood) in the treatment of anxiety. They include St John’s wort, Schisandra, lemon balm, skullcap, oats and damiana
• Spasmolytic herbs to alleviate spasm. Cramp bark and chamomile may be useful for any visceral symptoms associated with the anxiety, and hawthorn berry can be prescribed where there are cardiac symptoms. Motherwort is also useful for palpitations
• Anxious patients stress their bodies and deplete their adrenal reserves. This can create a vicious cycle. Hence adrenal restorative, adaptogenic and tonic herbs may be required. The herb of choice in this context is Withania, since it has calming properties, supported by Rehmannia and licorice (Glycyrrhiza)
• Patients who have access to a bath can be advised to add a few drops of lavender oil to the bath for its calming effect
• Any associated sleep disturbance should be treated with a separate formula at night (see Insomnia in this section)
• Anxiolytic herbs can be used to aid the withdrawal of benzodiazepine drugs. The herbs should be taken for a few weeks before the drugs are gradually withdrawn. Additive effects to the benzodiazepines are minimal.
Anxiolytic herbs should not in general make the patient drowsy or affect their capacity to drive or use machinery. However, some sensitive patients may complain of this. These are usually people who are sleep-deprived or ‘living on their nerves’ and the herbs are probably only making them aware of how tired their bodies are. Due attention to rest and sleep usually eliminates this effect over a few weeks.
Note: Terminology to describe the classification of medicines is often applied loosely and inconsistently in modern usage. Sedatives (according to the Oxford Dictionary) soothe the nervous system. Implied in the term, however, is a resultant state of sedation. In contrast, anxiolytics allay anxiety, without necessarily inducing a state of sedation. In modern parlance, sedatives are often used to describe substances that induce sleep. But the correct term for this is hypnotic. That said, it is obvious that most sedatives will assist someone with disturbed sleep (but probably work better as such when taken throughout the day, rather than just before bed).
Valeriana officinalis | 1:2 | 20 mL |
Passiflora incarnata | 1:2 | 20 mL |
Withania somnifera | 1:2 | 35 mL |
Hypericum perforatum | 1:2 | 25 mL |
total | 100 mL |
Dose: 8 mL with water twice a day.
Case history
A female patient aged 45 was suffering from anxiety and depression and had been diagnosed as having bipolar disorder and prescribed lithium and dothiepin hydrochloride. Three years ago she experienced a nervous breakdown. She had recently left a difficult and unstable husband, whom she felt had persecuted her. The dothiepin caused side effects so the patient had recently discontinued it.
The patient was prescribed the following herbs:
Hypericum perforatum | 1:2 | 20 mL |
Piper methysticum | 1:2 | 25 mL |
Scutellaria lateriflora | 1:2 | 15 mL |
Valeriana officinalis | 1:2 | 20 mL |
Bacopa monniera | 1:2 | 20 mL |
total | 100 mL |
Dose: 5 mL with water three times a day.
Also, to help with sleep, valerian tablets 500 mg, three before bed were suggested. After taking the herbs for 4 weeks she reported that she felt better in herself and was coping well and her sleep had improved. She continued on the herbs for another 6 months with good results. (The patient was also recommended to consult a clinical psychologist skilled in counselling, which she did.)
Note: Bacopa was included in the formula because of its use in India for extreme mental states. Kava might be substituted with tablets or capsules if a liquid is not available. Alternatively other herbs such as Corydalis could have been used instead of the kava.